CN106507673A - 6‑氯取代的咪唑并[1,2‑a]吡啶甲酰胺及其作为可溶性鸟苷酸环化酶刺激剂的用途 - Google Patents
6‑氯取代的咪唑并[1,2‑a]吡啶甲酰胺及其作为可溶性鸟苷酸环化酶刺激剂的用途 Download PDFInfo
- Publication number
- CN106507673A CN106507673A CN201580034595.5A CN201580034595A CN106507673A CN 106507673 A CN106507673 A CN 106507673A CN 201580034595 A CN201580034595 A CN 201580034595A CN 106507673 A CN106507673 A CN 106507673A
- Authority
- CN
- China
- Prior art keywords
- salt
- oxides
- compound
- solvate
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000460 chlorine Substances 0.000 title abstract description 7
- 229910052801 chlorine Inorganic materials 0.000 title abstract description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 title abstract description 5
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 title abstract description 4
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title description 11
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title description 11
- 229940118547 Guanylate cyclase stimulant Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 208
- 238000000034 method Methods 0.000 claims description 86
- 150000003839 salts Chemical class 0.000 claims description 77
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 65
- 239000002904 solvent Substances 0.000 claims description 63
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 59
- 239000002585 base Substances 0.000 claims description 36
- 239000012453 solvate Substances 0.000 claims description 36
- 239000011737 fluorine Substances 0.000 claims description 34
- 229910052731 fluorine Inorganic materials 0.000 claims description 34
- 235000005152 nicotinamide Nutrition 0.000 claims description 33
- 239000011570 nicotinamide Substances 0.000 claims description 32
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 22
- 230000009897 systematic effect Effects 0.000 claims description 18
- 206010019280 Heart failures Diseases 0.000 claims description 15
- 239000003513 alkali Substances 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 12
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 10
- 210000001367 artery Anatomy 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 201000006370 kidney failure Diseases 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 230000036772 blood pressure Effects 0.000 claims description 9
- 230000000302 ischemic effect Effects 0.000 claims description 9
- 230000009424 thromboembolic effect Effects 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- 206010059245 Angiopathy Diseases 0.000 claims description 7
- 208000034189 Sclerosis Diseases 0.000 claims description 7
- 208000019553 vascular disease Diseases 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims 3
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 139
- 239000000203 mixture Substances 0.000 description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
- 239000000243 solution Substances 0.000 description 80
- 239000012071 phase Substances 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 61
- 150000002924 oxiranes Chemical class 0.000 description 54
- 235000002639 sodium chloride Nutrition 0.000 description 50
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 49
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 32
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000000376 reactant Substances 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- -1 NO Compound Chemical class 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 229910021529 ammonia Inorganic materials 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 229910052786 argon Inorganic materials 0.000 description 15
- 239000007789 gas Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 13
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 13
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 13
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 13
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 12
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 239000007821 HATU Substances 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- XMGMFRIEKMMMSU-UHFFFAOYSA-N phenylmethylbenzene Chemical group C=1C=CC=CC=1[C]C1=CC=CC=C1 XMGMFRIEKMMMSU-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000003613 bile acid Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000003176 fibrotic effect Effects 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- HCSHUEPPBIJJCB-UHFFFAOYSA-N carbamic acid;2,2,2-trifluoroacetic acid Chemical compound NC(O)=O.OC(=O)C(F)(F)F HCSHUEPPBIJJCB-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003087 receptor blocking agent Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 235000011167 hydrochloric acid Nutrition 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 4
- 102000014469 Guanylate cyclase Human genes 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 229940086609 Lipase inhibitor Drugs 0.000 description 4
- 102000057248 Lipoprotein(a) Human genes 0.000 description 4
- 108010033266 Lipoprotein(a) Proteins 0.000 description 4
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 229940083712 aldosterone antagonist Drugs 0.000 description 4
- 239000002416 angiotensin derivative Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 4
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 description 4
- 229960001208 eplerenone Drugs 0.000 description 4
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 4
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002461 renin inhibitor Substances 0.000 description 4
- 229940086526 renin-inhibitors Drugs 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
- VRLJFRODHVSTIK-UHFFFAOYSA-N 2-(benzhydrylideneamino)acetonitrile Chemical compound C=1C=CC=CC=1C(=NCC#N)C1=CC=CC=C1 VRLJFRODHVSTIK-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 0 CC(CCF)(CNC(c1c(C)nc(C(OCC2C(F)=CCCC2F)=C2)[N]1(C)C=C2Cl)=O)N Chemical compound CC(CCF)(CNC(c1c(C)nc(C(OCC2C(F)=CCCC2F)=C2)[N]1(C)C=C2Cl)=O)N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 229920002905 Colesevelam Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960002274 atenolol Drugs 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 229950010535 razaxaban Drugs 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 108091006084 receptor activators Proteins 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960002256 spironolactone Drugs 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 2
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical class CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 2
- REBAWHWWWIHOCJ-UHFFFAOYSA-N 2-fluoro-2-methylpropanenitrile Chemical compound CC(C)(F)C#N REBAWHWWWIHOCJ-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical class CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 2
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000165940 Houjia Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010027525 Microalbuminuria Diseases 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- IPGLIOFIFLXLKR-AXYNENQYSA-N adaprolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)C[C@@H](C3)C[C@H]2C[C@@H]3C1 IPGLIOFIFLXLKR-AXYNENQYSA-N 0.000 description 2
- 229950000221 adaprolol Drugs 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229960004601 aliskiren Drugs 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229960002213 alprenolol Drugs 0.000 description 2
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960002414 ambrisentan Drugs 0.000 description 2
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 229950010046 avasimibe Drugs 0.000 description 2
- 229950003799 axitirome Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229960004324 betaxolol Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002781 bisoprolol Drugs 0.000 description 2
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
- 108010055460 bivalirudin Proteins 0.000 description 2
- 229960001500 bivalirudin Drugs 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229960003065 bosentan Drugs 0.000 description 2
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229950005341 bucindolol Drugs 0.000 description 2
- 229960004064 bumetanide Drugs 0.000 description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 2
- 229960000330 bupranolol Drugs 0.000 description 2
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960000932 candesartan Drugs 0.000 description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 229910002090 carbon oxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 229960002320 celiprolol Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229960003850 dabigatran Drugs 0.000 description 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 2
- FEJVSJIALLTFRP-LJQANCHMSA-N darusentan Chemical compound COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 FEJVSJIALLTFRP-LJQANCHMSA-N 0.000 description 2
- 229950008833 darusentan Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229960005227 delapril Drugs 0.000 description 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002711 epanolol Drugs 0.000 description 2
- 229960003745 esmolol Drugs 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- 230000000058 esterolytic effect Effects 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- FUBBWDWIGBTUPQ-UHFFFAOYSA-N ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate Chemical compound CC1=CC(NC(=O)C(=O)OCC)=CC(C)=C1OC1=CC=C(O)C(C(O)C=2C=CC(F)=CC=2)=C1 FUBBWDWIGBTUPQ-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229950005809 implitapide Drugs 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 description 2
- 229950005241 landiolol Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 2
- 229960002137 melagatran Drugs 0.000 description 2
- 229960003134 mepindolol Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229960002704 metipranolol Drugs 0.000 description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 2
- 229960004027 molsidomine Drugs 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 229960000619 nebivolol Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 2
- 229950009478 otamixaban Drugs 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229960004570 oxprenolol Drugs 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229960001085 piretanide Drugs 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229960000206 potassium canrenoate Drugs 0.000 description 2
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 229960001148 rivaroxaban Drugs 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 2
- 229960002578 sitaxentan Drugs 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 229950004437 tiqueside Drugs 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- 229960003425 tirofiban Drugs 0.000 description 2
- 229960005461 torasemide Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001288 triamterene Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 2
- 229960001522 ximelagatran Drugs 0.000 description 2
- 229960000537 xipamide Drugs 0.000 description 2
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 2
- DMYZJLOWGSRVKP-RTBURBONSA-N (2r,4r)-1-n-(4-chlorophenyl)-4-hydroxy-2-n-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide Chemical compound N1([C@H](C[C@H](C1)O)C(=O)NC=1C=CC(=CC=1)N1C(COCC1)=O)C(=O)NC1=CC=C(Cl)C=C1 DMYZJLOWGSRVKP-RTBURBONSA-N 0.000 description 1
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LBRHUMBEGYYRBE-UHFFFAOYSA-N 1,1-difluoro-1-iodoethane Chemical compound CC(F)(F)I LBRHUMBEGYYRBE-UHFFFAOYSA-N 0.000 description 1
- ZUCFGSAENWHFPO-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrate;hydrochloride Chemical compound O.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 ZUCFGSAENWHFPO-UHFFFAOYSA-N 0.000 description 1
- PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
- CMLUGNQVANVZHY-POURPWNDSA-N 2-[1-[2-[(3r,5s)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5h-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N(CC(C)(C)COC(C)=O)C(=O)[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC CMLUGNQVANVZHY-POURPWNDSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UOJMJBUYXYEPFX-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-dimethylanilino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(NC(=O)C(O)=O)=CC=2C)C)=C1 UOJMJBUYXYEPFX-UHFFFAOYSA-N 0.000 description 1
- TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 description 1
- QHVBWSIFLCIXBD-UHFFFAOYSA-N 2-[[2-[3-(diaminomethylidene)-6-oxocyclohexa-1,4-dien-1-yl]oxy-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid Chemical compound N=1C(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC1=CC(=C(N)N)C=CC1=O QHVBWSIFLCIXBD-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- PSGASDJUCYTRAD-UHFFFAOYSA-N 3-chloro-2-nitropyridine Chemical class [O-][N+](=O)C1=NC=CC=C1Cl PSGASDJUCYTRAD-UHFFFAOYSA-N 0.000 description 1
- SCJCDNUXDWFVFI-UHFFFAOYSA-N 4,4,4-trifluorobutanal Chemical compound FC(F)(F)CCC=O SCJCDNUXDWFVFI-UHFFFAOYSA-N 0.000 description 1
- NOBZETMXGVAWIM-UHFFFAOYSA-N 4-[(2-carbamimidoyl-3,4-dihydro-1h-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C2CN(C(=N)N)CCC2=CC=C1OCC(CC1)(C(O)=O)CCN1C1=CC=NC=C1 NOBZETMXGVAWIM-UHFFFAOYSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101000988143 Antheraea pernyi Pheromone-binding protein 1 Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- LZFZLDBWYPXYCF-UHFFFAOYSA-N CC(=O)C.[F] Chemical compound CC(=O)C.[F] LZFZLDBWYPXYCF-UHFFFAOYSA-N 0.000 description 1
- NBOJBSGXGYDXLH-LLYPSXENSA-N CC(C1CC(NCC(C)(CCF)N)=[U])N=C(C(OC/C(/C(/F)=C\C)=C(/C)\F)=C2)N1C=C2Cl Chemical compound CC(C1CC(NCC(C)(CCF)N)=[U])N=C(C(OC/C(/C(/F)=C\C)=C(/C)\F)=C2)N1C=C2Cl NBOJBSGXGYDXLH-LLYPSXENSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 1
- 229920000230 Colestilan Polymers 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 229940121933 Cyclase stimulant Drugs 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical class C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- MZXKBYYEROJDAW-UHFFFAOYSA-N FC(F)CC(N=C(c1ccccc1)c1ccccc1)C#N Chemical compound FC(F)CC(N=C(c1ccccc1)c1ccccc1)C#N MZXKBYYEROJDAW-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101001057135 Homo sapiens Melanoma-associated antigen H1 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100027256 Melanoma-associated antigen H1 Human genes 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- WZHKCFDUDKJGBA-UHFFFAOYSA-N N1CCNCC1.S1C=CC=C1 Chemical class N1CCNCC1.S1C=CC=C1 WZHKCFDUDKJGBA-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 206010063985 Phytosterolaemia Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000008058 Reciprocating Tachycardia Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 108091006614 SLC10A2 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000002227 Sitosterolemia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000008131 Ventricular Flutter Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 1
- BKDZVPVJIXZYBH-UHFFFAOYSA-N [Na].C(C)(=O)O.NC(=N)N Chemical compound [Na].C(C)(=O)O.NC(=N)N BKDZVPVJIXZYBH-UHFFFAOYSA-N 0.000 description 1
- RINSMVSYCNNAGC-UHFFFAOYSA-N [bromo(difluoro)methyl]benzene Chemical class FC(F)(Br)C1=CC=CC=C1 RINSMVSYCNNAGC-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N ammonium carbonate Chemical class N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000011162 ammonium carbonates Nutrition 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 1
- 229950000285 anacetrapib Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UULYEWVRSIINDT-UHFFFAOYSA-N benzyl formate 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=COCC1=CC=CC=C1 UULYEWVRSIINDT-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
- 229960004634 carazolol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960004095 colestilan Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229950004181 dalcetrapib Drugs 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- PSMMNJNZVZZNOI-SJILXJHISA-N edoxaban tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 PSMMNJNZVZZNOI-SJILXJHISA-N 0.000 description 1
- 229950005925 eflucimibe Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940047562 eliquis Drugs 0.000 description 1
- XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950006127 embusartan Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229950010034 fidexaban Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-O hydron;1,3-oxazole Chemical compound C1=COC=[NH+]1 ZCQWOFVYLHDMMC-UHFFFAOYSA-O 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- BEHYAANJUKYBTH-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CN21 BEHYAANJUKYBTH-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LYVGOAYMIAQLHI-UHFFFAOYSA-N methyl 2-butyl-1-[[2-fluoro-4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-6-oxopyridine-4-carboxylate Chemical compound CCCCC1=CC(C(=O)OC)=CC(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1F LYVGOAYMIAQLHI-UHFFFAOYSA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical class CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 1
- MALMHIVBMJBNGS-UHFFFAOYSA-N n,n'-dipropylmethanediimine Chemical compound CCCN=C=NCCC MALMHIVBMJBNGS-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 229950003510 pactimibe Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
- 229950005482 pamaqueside Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- BZCGWAXQDLXLQM-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O.ClP(Cl)(Cl)=O BZCGWAXQDLXLQM-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940099315 rimadyl Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229940021384 salt irrigating solution Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000002098 selective ion monitoring Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- BQMKAHQKDSZAIQ-UHFFFAOYSA-N tetrasodium;iron(3+);nitroxyl anion;pentacyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] BQMKAHQKDSZAIQ-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 229960002415 trichloroethylene Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本申请涉及新的6‑氯‑取代的咪唑并[1,2‑a]吡啶‑3‑甲酰胺,其制备方法,其单独或以结合物形式用于治疗和/或预防疾病的用途,以及其用于制备用于治疗和/或预防疾病、尤其是用于治疗和/或预防心血管病症的药物的用途。
Description
本申请涉及新的6-氯-取代的咪唑并[1,2-a]吡啶-3-甲酰胺,其制备方法,其单独或以结合物形式用于治疗和/或预防疾病的用途,以及其用于制备用于治疗和/或预防疾病、尤其是用于治疗和/或预防心血管病症的药物的用途。
哺乳动物细胞中最重要的细胞传导系统之一是环一磷酸鸟苷(cGMP)。它与由内皮释放并传导激素和机械信号的一氧化氮(NO)一起形成了NO/cGMP系统。鸟苷酸环化酶催化由三磷酸鸟苷(GTP)至cGMP的生物合成。迄今已知的该家族的代表可以按照结构特征或按照配体类型分为两组:可被利钠肽刺激的颗粒状鸟苷酸环化酶,和可被NO刺激的可溶性鸟苷酸环化酶。可溶性鸟苷酸环化酶由两个亚单元组成并且每个异源二聚体很可能包含一个血红素,血红素是调节中心的一部分。这对激活机制至关重要。NO能够与血红素的铁原子结合并因此显著地增加酶的活性。相反,不含血红素的制剂不能被NO刺激。一氧化碳(CO)也能够与血红素的中心铁原子结合,但是由CO进行的刺激比由NO进行的刺激少得多。
通过形成cGMP,以及由此产生的磷酸二酯酶、离子通道和蛋白激酶的调节,鸟苷酸环化酶在多种生理过程中起着重要的作用,特别是在平滑肌细胞的舒张和增殖中、在血小板聚集和血小板粘附中和在神经信号传导中,以及在基于上述过程中断的病症中。在病理生理学条件下,NO/cGMP系统可被抑制,这可导致,例如,高血压、血小板激活、细胞增殖增加、内皮功能障碍、动脉粥样硬化、心绞痛、心力衰竭、心肌梗塞、血栓形成、中风和性功能障碍。
由于预期的高效率和低水平的副作用,通过把影响有机体中的cGMP信号通路作为目标而对这类病症进行可能的NO非依赖性治疗是有前景的方法。
迄今为止,对于可溶性鸟苷酸环化酶的治疗性刺激,仅使用了基于NO发挥作用的化合物如有机硝酸酯。NO通过生物转化形成并且通过攻击血红素的中心铁原子来激活可溶性鸟苷酸环化酶。除了副作用外,耐受性的发展也是这种治疗模式的关键性缺点之一。
近年来,已经记载了一些直接(即无需事先释放NO)刺激可溶性鸟苷酸环化酶的物质,例如,3-(5'-羟甲基-2'-呋喃基)-1-苄基吲唑[YC-1;Wu等人,Blood 84(1994),4226;Mülsch等人,Brit.J.Pharmacol.120(1997),681]、脂肪酸[Goldberg等人,J.Biol.Chem.252(1977),1279]、二苯基碘鎓六氟磷酸盐[Pettibone等人,Eur.J.Pharmacol.116(1985),307]、异甘草素[Yu等人,Brit.J.Pharmacol.114(1995),1587]和各种取代的吡唑衍生物(WO 98/16223)。
可用于治疗病症的各种咪唑并[1,2-a]吡啶衍生物尤其记载于EP 0 266 890-A1、WO 89/03833-A1、JP 01258674-A[参见Chem.Abstr.112:178986]、WO 96/34866-A1、EP 1277 754-A1、WO 2006/015737-A1、WO 2008/008539-A2、WO 2008/082490-A2、WO 2008/134553-A1、WO 2010/030538-A2、WO 2011/113606-A1和WO 2012/165399-A1中。
本发明的一个目的是提供用作可溶性鸟苷酸环化酶的刺激剂并且其本身适合于治疗和/或预防疾病的新物质。
本发明提供选自以下的化合物及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物
ent-N-(2-氨基-3-氟-2-甲基丙基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
和
ent-N-(2-氨基-5,5,5-三氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
和
ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
和
ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
和
ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
和
ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
和
rac-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(外消旋体)
和
ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
和
ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
在本发明的上下文中,优选的盐为本发明化合物的生理上可接受的盐。还包括其本身不适于药学应用但可用于例如分离或纯化本发明的化合物的盐。
本发明化合物的生理上可接受的盐包括无机酸、羧酸和磺酸的酸加成盐,例如盐酸、氢溴酸、硫酸、磷酸、甲磺酸、乙磺酸、甲苯磺酸、苯磺酸、萘二磺酸、甲酸、乙酸、三氟乙酸、丙酸、乳酸、酒石酸、苹果酸、柠檬酸、富马酸、马来酸和苯甲酸的盐。
本发明化合物的生理上可接受的盐还包括常规碱的盐,例如并优选碱金属盐(例如钠盐和钾盐)、碱土金属盐(例如钙盐和镁盐)以及衍生自氨或具有1至16个碳原子的有机胺的铵盐,所述有机胺例如并优选乙胺、二乙胺、三乙胺、乙基二异丙基胺、单乙醇胺、二乙醇胺、三乙醇胺、二环己基胺、二甲基氨基乙醇、普鲁卡因、二苄基胺、N-甲基吗啉、精氨酸、赖氨酸、乙二胺和N-甲基哌啶。
在本发明的上下文中,溶剂合物被描述为通过与溶剂分子配位而形成固态或液态络合物的本发明化合物的那些形式。水合物是溶剂合物的一种具体形式,其中与水进行配位。在本发明的上下文中优选的溶剂合物为水合物。
根据其结构,本发明的化合物可以不同的立体异构形式存在,即以构型异构体的形式存在,或——如果合适——以构象异构体(对映异构体和/或非对映异构体,包括在阻转异构体的情况下的那些)的形式存在。因此,本发明包括对映异构体和非对映异构体及其各自的混合物。可以用已知的方法从所述对映异构体和/或非对映异构体的混合物中分离立体异构上一致的成分;为此目的优选使用色谱法,尤其是在非手性相或手性相上的HPLC色谱法。
如果本发明的化合物可以互变异构的形式存在,则本发明包括所有的互变异构形式。
本发明还包含本发明的化合物的所有合适的同位素变体。在本文中,本发明的化合物的同位素变体理解为意指这样的化合物:其中本发明的化合物中的至少一个原子被替换为具有相同原子序数但原子质量与在自然界中通常或主要存在的原子质量不同的另一原子。可纳入本发明的化合物的同位素的实例为氢、碳、氮、氧、磷、硫、氟、氯、溴和碘的同位素,如2H(氘)、3H(氚)、13C、14C、15N、17O、18O、32P、33P、33S、34S、35S、36S、18F、36Cl、82Br、123I、124I、129I和131I。本发明的化合物的特定同位素变体,尤其是其中已纳入一种或多种放射性同位素的变体,可有益于例如检查机体内的作用机理或活性化合物的分布;由于相对容易的可制备性和可检测性,用3H或14C同位素标记的化合物尤其适合于此目的。此外,由于该化合物的更高的代谢稳定性,例如在体内的半衰期的延长或所需活性剂量的减少,同位素(例如氘)的纳入可产生特别的治疗益处;因此,本发明的化合物的此类修饰在一些情况下还可构成本发明的优选实施方案。本发明化合物的同位素变体可通过本领域技术人员已知的方法——例如通过下文进一步描述的方法以及在工作实施例中描述的方法,通过使用各自试剂和/或起始物料的相应同位素修饰——来制备。
此外,本发明还包括本发明化合物的前药。在本文中,术语“前药”指这样的化合物:本身可能有生物活性或无生物活性,但在其体内停留期间反应(例如通过代谢或水解)得到本发明的化合物。
在本发明的上下文中,术语“治疗(treatment)”或“治疗(treating)”包括抑制、延缓、检查、减轻、减弱、限制、减少、压制、驱除或治愈疾病、病状(condition)、病症、损伤或健康问题,或这些状态和/或这些状态的症状的发展、进程(course)或进展。在本文中术语“疗法(therapy)”理解为与术语“治疗(treatment)”同义。
在本发明的上下文中,术语“预防(prevention)”、“预防(prophylaxis)”和“阻止(preclusion)”同义使用且指的是避免或减少感染、经历、遭受或患有疾病、病状、病症、损伤或健康问题或这些状态和/或这些状态的症状的发展或演进的风险。
疾病、病状、病症、损伤或健康问题的治疗或预防可以是部分的或完全的。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-3-氟-2-甲基丙基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-5,5,5-三氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为rac-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(外消旋体)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
在本发明的上下文中,优选具有系统名称为ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
本发明还提供一种制备本发明化合物的方法,其特征在于
[A]式(I)的化合物
其中
T1代表(C1-C4)-烷基或苄基,
在惰性溶剂中在合适的碱或酸的存在下反应,得到式(II)的羧酸
随后在惰性溶剂中,在酰胺偶联条件下,与选自以下的胺反应,
任选在催化剂的存在下,将任选存在的保护基团氢解除去,
并且将所得到的化合物任选地使用合适的(i)溶剂和/或(ii)酸或碱转化成它们的溶剂合物、盐和/或所述盐的溶剂合物。
所述制备方法可例如通过以下合成方案(方案1)来说明:
方案1:
[a):氢氧化锂,THF/甲醇/H2O,RT;b):HATU,N,N-二异丙基乙胺,DMF,RT;c):于活性碳上的钯(10%),乙醇,氢,RT]。
式(III-A)、(III-B)、(III-C)、(III-D)和(III-E)的化合物市售可得或由文献获知,或可类似于文献方法制备。
用于酰胺偶联的合适的惰性溶剂为,例如,醚如乙醚、二噁烷、四氢呋喃、乙二醇二甲醚或二乙二醇二甲醚,烃如苯、甲苯、二甲苯、己烷、环己烷或矿物油馏分,卤代烃如二氯甲烷、三氯甲烷、四氯甲烷、1,2-二氯乙烷、三氯乙烯或氯苯,或其他溶剂如丙酮、乙酸乙酯、乙腈、吡啶、二甲基亚砜、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N,N'-二甲基丙烯基脲(DMPU)或N-甲基吡咯烷酮(NMP)。也可以使用所述溶剂的混合物。优选二氯甲烷、四氢呋喃、二甲基甲酰胺或这些溶剂的混合物。
适合于作为缩合剂用于酰胺形成的是,例如,碳二亚胺如N,N'-二乙基碳二亚胺、N,N'-二丙基碳二亚胺、N,N'-二异丙基碳二亚胺、N,N'-二环己基碳二亚胺(DCC)或N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐(EDC);光气衍生物如N,N'-羰基二咪唑(CDI);1,2-噁唑鎓(oxazolium)化合物如2-乙基-5-苯基-1,2-噁唑鎓3-硫酸盐或2-叔丁基-5-甲基异噁唑鎓高氯酸盐;酰氨基化合物如2-乙氧基-1-乙氧基羰基-1,2-二氢喹啉;或氯甲酸异丁酯;丙烷膦酸酐(T3P);1-氯-N,N,2-三甲基丙-1-烯-1-胺;氰基膦酸二乙酯;双(2-氧代-3-噁唑烷基)磷酰氯、苯并三唑-1-基氧基三(二甲基氨基)鏻六氟磷酸盐、苯并三唑-1-基氧基三(吡咯烷基)鏻六氟磷酸盐(PyBOP)、O-(苯并三唑-1-基)-N,N,N′,N′-四甲基脲四氟硼酸盐(TBTU)、O-(苯并三唑-1-基)-N,N,N′,N′-四甲基脲六氟磷酸盐(HBTU)、2-(2-氧代-1-(2H)-吡啶基)-1,1,3,3-四甲基脲四氟硼酸盐(TPTU)、O-(7-氮杂苯并三唑-1-基)-N,N,N′,N′-四甲基脲六氟磷酸盐(HATU)或O-(1H-6-氯苯并三唑-1-基)-1,1,3,3-四甲基脲四氟硼酸盐(TCTU),任选地与其他助剂(如1-羟基苯并三唑(HOBt)或N-羟基琥珀酰亚胺(HOSu))以及作为碱的碱金属碳酸盐(如碳酸钠或碳酸钾或碳酸氢钠或碳酸氢钾)或有机碱(如三烷基胺,例如三乙胺、N-甲基吗啉、N-甲基哌啶或N,N-二异丙基乙胺)结合。优选使用与N-甲基吗啉结合的TBTU、与N,N-二异丙基乙胺结合的HATU或1-氯-N,N,2-三甲基丙-1-烯-1-胺。
缩合通常在-20℃至+100℃的温度范围内进行,优选在0℃至+60℃下进行。所述转化可在大气压、加压或减压(例如0.5至5巴)下进行。通常,所述反应在大气压下进行。
或者,也可以首先将式(II)的羧酸转化成相应的碳酰氯,然后可以将所述碳酰氯直接或在单独的反应中用式(III)的胺转化成本发明化合物。由羧酸形成碳酰氯通过本领域技术人员已知的方法进行,例如通过任选在合适的惰性溶剂中,在合适的碱的存在下,例如在吡啶的存在下以及任选地加入二甲基甲酰胺,用亚硫酰氯、磺酰氯或草酰氯处理。
式(I)的化合物中的酯基T1的水解通过常规方法通过在惰性溶剂中用酸或碱处理酯而进行,在后者的情况下,将起初形成的盐通过酸处理而转化成游离羧酸。在叔丁酯的情况下,酯水解优选用酸进行。在苄基酯的情况下,酯裂解优选通过用于活性碳上的钯或雷尼镍氢解而进行。用于该反应的合适的惰性溶剂为水或常规用于酯水解的有机溶剂。这些有机溶剂优选包括醇如甲醇、乙醇、正丙醇、异丙醇、正丁醇或叔丁醇,或醚如乙醚、四氢呋喃、2-甲基四氢呋喃、二噁烷或乙二醇二甲醚,或其他溶剂如丙酮、二氯甲烷、二甲基甲酰胺或二甲基亚砜。也可以使用所述溶剂的混合物。在碱性酯水解的情况下,优选使用水与二噁烷、四氢呋喃、甲醇和/或乙醇的混合物。
用于酯水解的合适的碱为常规无机碱。其优选包括碱金属氢氧化物或碱土金属氢氧化物,例如氢氧化钠、氢氧化锂、氢氧化钾或氢氧化钡;或碱金属碳酸盐或碱土金属碳酸盐,如碳酸钠、碳酸钾或碳酸钙。特别优选氢氧化钠或氢氧化锂。
用于酯裂解的合适的酸通常为硫酸、氯化氢/盐酸、溴化氢/氢溴酸、磷酸、乙酸、三氟乙酸、甲苯磺酸、甲磺酸或三氟甲磺酸,或其混合物,任选加入水。在叔丁酯的情况下,优选氯化氢或三氟乙酸,在甲酯的情况下,优选盐酸。
酯水解通常在0℃至+100℃的温度范围内进行,优选在+0℃至+50℃下进行。
这些转化可在大气压、加压或减压(例如0.5至5巴)下进行。通常,所述反应在每种情况下都在大气压下进行。
所使用的氨基保护基团优选为叔丁氧基羰基(Boc)或苄氧基羰基(Z)。用于羟基或羧基官能团的保护基团优选为叔丁基或苄基。这些保护基团通过常规方法脱除,优选通过在惰性溶剂如二噁烷、乙醚、二氯甲烷或乙酸中与强酸如氯化氢、溴化氢或三氟乙酸反应;任选也可以在没有额外的惰性溶剂的情况下实现所述脱除。在苄基和苄氧基羰基作为保护基团的情况下,其也可通过在钯催化剂的存在下氢解除去。所述保护基团的脱除可任选地在一锅反应中同时进行或在单独的反应步骤中进行。
在本文中,苄基的去除通过由保护基团化学已知的常规方法进行,优选通过在钯催化剂(例如于活性碳上的钯)的存在下在惰性溶剂(例如乙醇或乙酸乙酯)中氢解[还参见,例如,T.W.Greene和P.G.M.Wuts,Protective Groups in Organic Synthesis,Wiley,New York,1999]。
式(I)的化合物由文献获知或可通过如下方法制备:在惰性溶剂中,在合适的碱的存在下,使式(IV)的化合物
与式(V)的化合物反应
其中
X1代表合适的离去基团,特别是氯、溴、碘、甲磺酸根、三氟甲磺酸根(triflate)或甲苯磺酸根,
得到式(VI)的化合物
然后使其在惰性溶剂中与式(VII)的化合物反应
其中T1具有以上给出的含义。
所述方法以示例性方式通过以下方案(方案2)来说明:
方案2:
[a):i)NaOMe,MeOH,RT;ii)DMSO,RT;b):EtOH,分子筛,回流]。
可修改所示合成顺序,使得各反应步骤以不同的次序进行。这样修改的合成顺序的实例示于方案3中。
方案3:
[a):EtOH,分子筛,回流;b):b)Cs2CO3,DMF,50℃]。
用于环合以得到咪唑并[1,2-a]吡啶碱骨架(VI)+(VII)→(I)或(IV)+(VII)→(VIII)的惰性溶剂为常规有机溶剂。其优选包括醇如甲醇、乙醇、正丙醇、异丙醇、正丁醇、正戊醇或叔丁醇,或醚如乙醚、四氢呋喃、2-甲基四氢呋喃、二噁烷或乙二醇二甲醚,或其他溶剂如丙酮、二氯甲烷、1,2-二氯乙烷、乙腈、二甲基甲酰胺或二甲基亚砜。也可以使用所述溶剂的混合物。优选使用乙醇。
所述环合通常在+50℃至+150℃的温度范围内进行,优选在+50℃至+100℃下进行,任选在微波中进行。
环合(VI)+(VII)→(I)或(IV)+(VII)→(VIII)任选地在脱水反应添加剂的存在下进行,例如在分子筛(孔径)的存在下或借助水分离器进行。反应(VI)+(VII)→(I)或(IV)+(VII)→(VIII)使用过量的式(VII)的试剂,例如用1至20当量的试剂(VII),任选加入碱(例如碳酸氢钠)进行,在这种情况下,该试剂的添加可以一次性或分几个部分进行。
作为方案1至3中所示的引入2,6-二氟苄基的替代方案,还可以——如方案4中所示——使这些中间体在Mitsunobu反应的条件下与式(IX)的醇反应。
方案4:
其中
R1代表式(III-A)、(III-B)、(III-C)、(III-D)和(III-E)的化合物
并且
其中T1具有以上给出的含义。
酚与醇的这种Mitsunobu缩合的典型反应条件可见于相关文献,例如Hughes,D.L.Org.React.1992,42,335;Dembinski,R.Eur.J.Org.Chem.2004,2763。通常,所述反应使用活化剂如偶氮二甲酸二乙酯(DEAD)或偶氮二甲酸二异丙酯(DIAD)和膦试剂如三苯基膦或三丁基膦,在惰性溶剂(如THF、二氯甲烷、甲苯或DMF)中在0℃和所用试剂的沸点之间的温度下进行。
本发明的化合物具有有价值的药理学特性并可用于预防和治疗人和动物的疾病。本发明的化合物提供了另一种治疗替代方案并因此扩大了药学领域。
本发明的化合物引起血管舒张和血小板聚集的抑制并导致血压降低和冠状动脉血流量增加。这些效果通过可溶性鸟苷酸环化酶的直接刺激和细胞内cGMP的增加来介导。此外,本发明的化合物增强了增加cGMP水平的物质的活性,所述物质例如EDRF(内皮衍生的舒张因子)、NO供体、原卟啉IX、花生四烯酸或苯肼衍生物。
本发明的化合物适合于治疗和/或预防心血管病症、肺病症、血栓栓塞性病症和纤维化的病症。
因此,可将本发明的化合物用于治疗和/或预防以下的药物中:心血管病症,例如,高血压(血压升高)、难治性高血压、急性和慢性心力衰竭、冠心病、稳定型和不稳定型心绞痛、外周和心血管病症、心律失常、房性和室性心律失常,以及受损传导,例如,I-III度房室传导阻滞(AB阻滞I-III)、室上快速性心律失常、心房颤动、心房扑动、心室颤动、心室扑动、室性快速性心律失常、尖端扭转型室性心动过速、房性和室性早搏、AV-交接区性期前收缩(AV-junctional extrasystole)、病态窦房结综合征、晕厥、AV-结折返性心动过速、沃-帕-怀综合征(Wolff-Parkinson-White syndrome);急性冠状动脉综合征(ACS)、自身免疫性心脏病症(心包炎、心内膜炎、心脏瓣膜炎(valvolitis)、主动脉炎、心肌病)、休克(如心源性休克、感染性休克和过敏性休克)、动脉瘤、拳师犬心肌病(boxer cardiomyopathy)(心室早发性收缩(PVC));用于治疗和/或预防以下疾病的药物中:血栓栓塞病症和局部缺血,如心肌缺血、心肌梗塞、中风、心脏肥大、短暂性和局部缺血性发作、先兆子痫、炎性心血管病症、冠状动脉和外周动脉痉挛,水肿形成如肺水肿、脑水肿、肾水肿或由心力衰竭引起的水肿、外周循环障碍、再灌注损伤、动脉和静脉血栓形成、微量清蛋白尿、心肌功能不全、内皮功能紊乱;用以预防再狭窄,例如溶栓治疗后、经皮腔内血管成形术(PTA)后、经腔内冠状动脉血管成形术(PTCA)后、心脏移植和搭桥手术后的再狭窄,以及微血管和大血管损伤(血管炎)、增高水平的纤维蛋白原和低密度脂蛋白(LDL)和增高浓度的纤溶酶原激活物抑制剂1(PAI-1);以及用于治疗和/或预防勃起功能障碍和女性性功能障碍。
在本发明的上下文中,术语“心力衰竭”包括心力衰竭的急性和慢性形式,以及更具体或相关的疾病类型,如急性代偿失调性心力衰竭、右心衰竭、左心衰竭、全心衰竭(global failure)、缺血性心肌病、扩张型心肌病、肥大型心肌病、特发性心肌病、先天性心脏缺陷、与心脏瓣膜缺损相关的心力衰竭、二尖瓣狭窄、二尖瓣闭锁不全、主动脉瓣狭窄、主动脉瓣闭锁不全、三尖瓣狭窄、三尖瓣闭锁不全、肺动脉瓣狭窄、肺动脉瓣闭锁不全、复合性心脏瓣膜缺损(combined heart valve defect)、心肌炎症(心肌炎)、慢性心肌炎、急性心肌炎、病毒性心肌炎、糖尿病性心力衰竭、酒精性心肌病、心脏储积病症(cardiac storagedisorder)、舒张性心力衰竭和收缩性心力衰竭,以及现有的慢性心力衰竭恶化的急性期(恶化的心力衰竭)。
此外,本发明的化合物还可用于治疗和/或预防动脉硬化、受损的脂类代谢、低脂蛋白血症、血脂异常(dyslipidaemias)、高甘油三酯血症、高脂血症、高胆固醇血症、无β脂蛋白血症、谷甾醇血症、黄瘤病、丹吉尔病、肥胖(adiposity)、肥胖症(obesity),以及混合性高脂血症(combined hyperlipidaemias)和代谢综合征。
本发明的化合物还可用于治疗和/或预防原发性和继发性雷诺现象、微循环障碍、跛行、外周和自主神经病、糖尿病性微血管病、糖尿病视网膜病、糖尿病四肢溃疡、坏疽、CREST综合征、红斑病(erythematosis)、甲癣、风湿病症,以及用于促进伤口愈合。
本发明的化合物还适于治疗泌尿系统病症,例如,良性前列腺综合征(BPS)、良性前列腺增生(BPH)、良性前列腺增大(BPE)、膀胱出口梗阻(BOO)、下泌尿道综合征(LUTS,包括猫泌尿综合征(FUS));泌尿生殖系统病症,包括神经源性膀胱过度活动症(OAB)和(IC)、失禁(UI)(例如混合性尿失禁、急迫性尿失禁、压迫性尿失禁或溢流性尿失禁(MUI、UUI、SUI、OUI))、骨盆痛、男性和女性泌尿生殖系统器官的良性和恶性病症。
本发明的化合物还适于治疗和/或预防肾病,特别是急性和慢性肾功能不全以及急性和慢性肾衰竭。在本发明的上下文中,术语“肾功能不全”包括肾功能不全的急性和慢性表现,以及潜在或相关的肾脏病症如肾血流灌注不足、透析时低血压、梗阻性尿路病、肾小球病、肾小球肾炎、急性肾小球肾炎、肾小球硬化症、肾小管间质疾病,肾病病症如原发性和先天性肾病、肾炎、免疫性肾病如肾移植排斥和免疫复合物诱导的肾病、有毒物质诱导的肾病、造影剂诱导的肾病、糖尿病和非糖尿病肾病、肾盂肾炎、肾囊肿、肾硬化、高血压性肾硬化以及肾病综合征,所述肾病综合征可具有以下诊断特征,例如肌酸酐和/或水排泄的异常减少,尿素、氮、钾和/或肌酸酐的血液浓度异常升高,肾脏酶(例如谷酰基合成酶)的活性改变,尿液渗透压或尿量的改变,微量清蛋白尿的增加,大量清蛋白尿的增加,肾小球和小动脉的损害,肾小管扩张,高磷酸盐血症和/或需要透析。本发明还包括本发明的化合物用于治疗和/或预防肾功能不全后遗症的用途,例如肺水肿、心力衰竭、尿毒症、贫血、电解质紊乱(例如高钾血症、低钠血症)以及骨代谢和碳水化合物代谢紊乱。
此外,本发明的化合物还适于治疗和/或预防哮喘病症、肺动脉高血压(PAH)和其他形式的肺高血压(PH),所述其他形式的肺高血压包括与左心疾病、HIV、镰状细胞贫血、血栓栓塞(CTEPH)、结节病、COPD或肺纤维化相关的肺高血压;慢性阻塞性肺疾病(COPD);急性呼吸窘迫综合征(ARDS);急性肺损伤(ALI);α-1-抗胰蛋白酶缺乏(AATD);肺纤维化;肺气肿(例如香烟烟雾诱导的肺气肿)和囊性纤维化(CF)。
本发明描述的化合物也是用于控制以NO/cGMP系统紊乱为特征的中枢神经系统病症的活性成分。它们特别适于在认知损伤后提高知觉、注意力、学习或记忆力,所述认知损伤例如特别是伴随状况/疾病/综合征发生的认知损伤,如轻度认知损伤、年龄相关的学习和记忆力减退、年龄相关的记忆丧失、血管性痴呆、颅脑创伤、中风、中风后发生的痴呆(中风后痴呆)、创伤后颅脑创伤、一般性注意力集中障碍、具有学习和记忆力问题的儿童的注意力集中障碍、阿尔茨海默病、路易体痴呆、伴随着额叶退化的痴呆(包括皮克氏综合征、帕金森病、进行性核性麻痹)、伴随着皮质基底退化的痴呆、肌萎缩性侧索硬化症(ALS)、亨廷顿氏舞蹈病、脱髓鞘作用、多发性硬化症、丘脑退化、克-雅病痴呆(Creutzfeldt-Jakobdementia)、HIV痴呆、伴随着痴呆的精神分裂症或科尔萨科夫氏精神病。它们还适于治疗和/或预防中枢神经系统病症如焦虑、紧张和抑郁状态,CNS相关的性功能障碍和睡眠障碍,以及适于控制食物、兴奋剂和成瘾物质的摄取的病理性紊乱。
此外,本发明的化合物还适于控制脑血流量并是控制偏头痛的有效药剂。它们还适于预防和控制脑梗塞后遗症(脑中风),如中风、脑缺血和颅脑创伤。本发明的化合物同样可用于控制疼痛和耳鸣状况。
此外,本发明的化合物有抗炎作用,并因此可用做治疗和/或预防以下疾病的抗炎药剂:败血症(SIRS)、多器官衰竭(MODS、MOF)、肾的炎症性病症、慢性肠炎(IBD、克罗恩氏病、UC)、胰腺炎、腹膜炎、风湿病症、炎症性皮肤病症和炎症性眼病症。
此外,本发明的化合物还可用于治疗和/或预防自身免疫性疾病。
本发明的化合物还适于治疗和/或预防内部器官(例如肺、心脏、肾、骨髓以及特别是肝)的纤维化病症,以及皮肤纤维化和眼的纤维化病症。在本发明的上下文中,术语纤维化病症特别包括以下术语:肝纤维化、肝硬化、肺纤维化、心内膜心肌纤维化、肾病、肾小球肾炎、间质性肾纤维化、由糖尿病引起的纤维化损伤、骨髓纤维化及类似的纤维化病症、硬皮病、硬斑病、瘢痕瘤、肥厚性瘢痕(还有手术后的肥厚性瘢痕)、痣、糖尿病视网膜病、增生性玻璃体视网膜病变和结缔组织病症(例如结节病)。
本发明的化合物还适于控制术后瘢痕,例如由青光眼手术导致的瘢痕。
本发明的化合物还可在美容方面用于老化和角质化皮肤。
此外,本发明的化合物适于治疗和/或预防肝炎、肿瘤、骨质疏松症、青光眼和胃轻瘫。
本发明还提供本发明的化合物用于治疗和/或预防病症、尤其是上述病症的用途。
本发明还提供本发明的化合物用于治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症、纤维化病症和动脉硬化的用途。
本发明还提供本发明的化合物,其用于治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症、纤维化病症和动脉硬化的方法中。
本发明还提供本发明的化合物用于制备用于治疗和/或预防病症、尤其是上述病症的药物的用途。
本发明还提供本发明的化合物用于制备用于治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症、纤维化病症和动脉硬化的药物的用途。
本发明还提供一种使用有效量的至少一种本发明的化合物来治疗和/或预防病症、特别是上述病症的方法。
本发明还提供一种使用有效量的至少一种本发明的化合物来治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症、纤维化病症和动脉硬化的方法。
本发明的化合物可以单独使用或——如果需要——可与其他活性化合物结合使用。本发明还提供包含至少一种本发明的化合物和一种或多种其他活性化合物的药物,其尤其是用于上述病症的治疗和/或预防。适于结合的活性成分的优选实例包括:
有机硝酸盐和NO供体,例如硝普钠、硝化甘油、单硝酸异山梨酯、二硝酸异山梨酯、吗多明(molsidomine)或SIN-1以及吸入性NO;
抑制环一磷酸鸟苷(cGMP)分解的化合物,例如磷酸二酯酶(PDE)1、2和/或5的抑制剂,尤其是PDE 5抑制剂如西地那非(sildenafil)、伐地那非(vardenafil)和他达拉非(tadalafil);
抗血栓形成剂,例如并优选选自血小板聚集抑制剂、抗凝血剂或致纤溶作用物质;
降血压的活性化合物,例如并优选选自钙拮抗剂、血管紧张素AII拮抗剂、ACE抑制剂、内皮素拮抗剂、肾素抑制剂、α-受体阻断剂、β-受体阻断剂、盐皮质激素受体拮抗剂,以及利尿剂;和/或
改变脂类代谢的活性化合物,例如并优选选自甲状腺受体激动剂,胆固醇合成抑制剂(例如并优选HMG-CoA还原酶抑制剂或鲨烯合成抑制剂),ACAT抑制剂,CETP抑制剂,MTP抑制剂,PPAR-α、PPAR-γ和/或PPAR-δ激动剂,胆固醇吸收抑制剂,脂肪酶抑制剂,聚合胆汁酸吸附剂,胆汁酸再吸收抑制剂和脂蛋白(a)拮抗剂。
抗血栓形成剂优选理解为意指选自以下的化合物:血小板聚集抑制剂、抗凝血剂或致纤溶作用物质。
在本发明的一个优选实施方案中,本发明的化合物与血小板聚集抑制剂结合给药,所述血小板聚集抑制剂例如并优选阿司匹林、氯吡格雷(clopidogrel)、噻氯匹定(ticlopidine)或双嘧达莫(dipyridamole)。
在本发明的一个优选实施方案中,本发明的化合物与凝血酶抑制剂结合给药,所述凝血酶抑制剂例如并优选希美加群(ximelagatran)、达比加群(dabigatran)、美拉加群(melagatran)、比伐卢定(bivalirudin)或克赛(clexane)。
在本发明的一个优选实施方案中,本发明的化合物与GPIIb/IIIa拮抗剂结合给药,所述GPIIb/IIIa拮抗剂例如并优选替罗非班(tirofiban)或阿昔单抗(abciximab)。
在本发明的一个优选实施方案中,本发明的化合物与Xa因子抑制剂结合给药,所述Xa因子抑制剂例如并优选利伐沙班(rivaroxaban)(BAY 59-7939)、DU-176b、阿哌沙班(apixaban)、奥米沙班(otamixaban)、非德沙班(fidexaban)、雷扎沙班(razaxaban)、磺达肝素(fondaparinux)、艾卓肝素(idraparinux)、PMD-3112、YM-150、KFA-1982、EMD-503982、MCM-17、MLN-1021、DX 9065a、DPC 906、JTV 803、SSR-126512或SSR-128428。
在本发明的一个优选实施方案中,本发明的化合物与肝素或具有低分子量(LMW)的肝素衍生物结合给药。
在本发明的一个优选实施方案中,本发明的化合物与维生素K拮抗剂(例如并优选香豆素)结合给药。
降血压剂优选理解为意指选自以下的化合物:钙拮抗剂、血管紧张素AII拮抗剂、ACE抑制剂、内皮素拮抗剂、肾素抑制剂、α-受体阻断剂、β-受体阻断剂、盐皮质激素受体拮抗剂和利尿剂。
在本发明的一个优选实施方案中,本发明的化合物与钙拮抗剂结合给药,所述钙拮抗剂例如并优选硝苯地平(nifedipine)、氨氯地平(amlodipine)、维拉帕米(verapamil)或地尔硫卓(diltiazem)。
在本发明的一个优选实施方案中,本发明的化合物与α-1-受体阻断剂结合给药,所述α-1-受体阻断剂例如并优选哌唑嗪(prazosin)。
在本发明的一个优选实施方案中,本发明的化合物与β-受体阻断剂结合给药,所述β-受体阻断剂例如并优选普萘洛尔(propranolol)、阿替洛尔(atenolol)、噻吗洛尔(timolol)、吲哚洛尔(pindolol)、阿普洛尔(alprenolol)、氧烯洛尔(oxprenolol)、喷布洛尔(penbutolol)、布拉洛尔(bupranolol)、美替洛尔(metipranolol)、纳多洛尔(nadolol)、甲吲洛尔(mepindolol)、卡拉洛尔(carazalol)、索他洛尔(sotalol)、美托洛尔(metoprolol)、倍他洛尔(betaxolol)、塞利洛尔(celiprolol)、比索洛尔(bisoprolol)、卡替洛尔(carteolol)、艾司洛尔(esmolol)、拉贝洛尔(labetalol)、卡维地洛(carvedilol)、阿达洛尔(adaprolol)、兰地洛尔(landiolol)、奈必洛尔(nebivolol)、依泮洛尔(epanolol)或布新洛尔(bucindolol)。
在本发明的一个优选实施方案中,本发明的化合物与血管紧张素AII拮抗剂结合给药,所述血管紧张素AII拮抗剂例如并优选氯沙坦(losartan)、坎地沙坦(candesartan)、缬沙坦(valsartan)、替米沙坦(telmisartan)或恩布沙坦(embursatan)。
在本发明的一个优选实施方案中,本发明的化合物与ACE抑制剂结合给药,所述ACE抑制剂例如并优选依那普利(enalapril)、卡托普利(captopril)、赖诺普利(lisinopril)、雷米普利(ramipril)、地拉普利(delapril)、福辛普利(fosinopril)、奎诺普利(quinopril)、培哚普利(perindopril)或川多普利(trandopril)。
在本发明的一个优选实施方案中,本发明的化合物与内皮素拮抗剂结合给药,所述内皮素拮抗剂例如并优选波生坦(bosentan)、达卢生坦(darusentan)、安立生坦(ambrisentan)或西他生坦(sitaxsentan)。
在本发明的一个优选实施方案中,本发明的化合物与肾素抑制剂结合给药,所述肾素抑制剂例如并优选阿利吉仑(aliskiren)、SPP-600或SPP-800。
在本发明的一个优选实施方案中,本发明的化合物与盐皮质激素受体拮抗剂结合给药,所述盐皮质激素受体拮抗剂例如并优选螺内酯(spironolactone)或依普利酮(eplerenone)。
在本发明的一个优选实施方案中,本发明的化合物与以下物质结合给药:袢利尿剂,例如呋塞米(furosemide)、托拉塞米(torasemide)、布美他尼(bumetanide)和吡咯他尼(piretanide);保钾利尿剂,例如阿米洛利(amiloride)和氨苯蝶啶(triamterene);醛固酮拮抗剂,例如螺内酯、坎利酸钾(potassium canrenoate)和依普利酮(eplerenone);以及噻嗪类利尿剂例如氢氯噻嗪(hydrochlorothiazide)、氯噻酮(chlorthalidone)、希帕胺(xipamide)和吲达帕胺(indapamide)。
脂类代谢调节剂优选理解为意指选自以下的化合物:CETP抑制剂,甲状腺受体激动剂,胆固醇合成抑制剂如HMG-CoA还原酶抑制剂或鲨烯合成抑制剂,ACAT抑制剂,MTP抑制剂,PPAR-α、PPAR-γ和/或PPAR-δ激动剂,胆固醇吸收抑制剂,聚合胆汁酸吸附剂,胆汁酸再吸收抑制剂,脂肪酶抑制剂和脂蛋白(a)拮抗剂。
在本发明的一个优选实施方案中,本发明的化合物与CETP抑制剂结合给药,所述CETP抑制剂例如并优选达塞曲匹(dalcetrapib)、BAY60-5521、安塞曲匹(anacetrapib)或CETP疫苗(CETi-1)。
在本发明的一个优选实施方案中,本发明的化合物与甲状腺受体激动剂结合给药,所述甲状腺受体激动剂例如并优选D-甲状腺素、3,5,3'-三碘甲状腺氨酸(T3)、CGS23425或阿昔替罗(axitirome)(CGS26214)。
在本发明的一个优选实施方案中,本发明的化合物与来自他汀类的HMG-CoA还原酶抑制剂结合给药,所述来自他汀类的HMG-CoA还原酶抑制剂例如并优选洛伐他汀(lovastatin)、辛伐他汀(simvastatin)、普伐他汀(pravastatin)、氟伐他汀(fluvastatin)、阿托伐他汀(atorvastatin)、罗舒伐他汀(rosuvastatin)或匹伐他汀(pitavastatin)。
在本发明的一个优选实施方案中,本发明的化合物与鲨烯合成抑制剂结合给药,所述鲨烯合成抑制剂例如并优选BMS-188494或TAK-475。
在本发明的一个优选实施方案中,本发明的化合物与ACAT抑制剂结合给药,所述ACAT抑制剂例如并优选阿伐麦布(avasimibe)、甲亚油酰胺(melinamide)、帕替麦布(pactimibe)、依鲁麦布(eflucimibe)或SMP-797。
在本发明的一个优选实施方案中,本发明的化合物与MTP抑制剂结合给药,所述MTP抑制剂例如并优选英普他派(implitapide)、BMS-201038、R-103757或JTT-130。
在本发明的一个优选实施方案中,本发明的化合物与PPAR-γ激动剂结合给药,所述PPAR-γ激动剂例如并优选吡格列酮(pioglitazone)或罗格列酮(rosiglitazone)。
在本发明的一个优选实施方案中,本发明的化合物与PPAR-δ激动剂结合给药,所述PPAR-δ激动剂例如并优选GW 501516或BAY68-5042。
在本发明的一个优选实施方案中,本发明的化合物与胆固醇吸收抑制剂结合给药,所述胆固醇吸收抑制剂例如并优选依泽替米贝(ezetimibe)、替奎安(tiqueside)或帕马苷(pamaqueside)。
在本发明的一个优选实施方案中,本发明的化合物与脂肪酶抑制剂结合给药,所述脂肪酶抑制剂例如并优选奥利司他(orlistat)。
在本发明的一个优选实施方案中,本发明的化合物与聚合胆汁酸吸附剂结合给药,所述聚合胆汁酸吸附剂例如并优选考来烯胺(cholestyramine)、考来替泊(colestipol)、考来维仑(colesolvam)、考来胶(CholestaGel)或考来替兰(colestimide)。
在本发明的一个优选实施方案中,本发明的化合物与胆汁酸再吸收抑制剂结合给药,所述胆汁酸再吸收抑制剂例如并优选ASBT(=IBAT)抑制剂,例如AZD-7806、S-8921、AK-105、BARI-1741、SC-435或SC-635。
在本发明的一个优选实施方案中,本发明的化合物与脂蛋白(a)拮抗剂结合给药,所述脂蛋白(a)拮抗剂例如并优选gemcabene calcium(CI-1027)或烟酸。
本发明还提供包含至少一种本发明的化合物、通常连同一种或多种惰性的、无毒的、药学上合适的赋形剂的药物,以及其用于上述目的的用途。
本发明的化合物可系统地和/或局部地作用。为此目的,其可以合适的方式给药,例如通过口服、肠胃外、肺、鼻、舌下、舌、颊、直肠、真皮、经皮、结膜或耳的途径给药,或作为植入物或支架给药。
本发明的化合物可以适于这些给药途径的给药形式给药。
用于口服给药的合适的给药形式为根据现有技术起作用并且快速和/或以缓和的方式释放本发明的化合物并且含有结晶和/或无定形和/或溶解形式的本发明的化合物的给药形式,例如片剂(未包衣或包衣片剂,例如具有控制本发明化合物的释放的抗胃液的包衣或延迟溶解的包衣或不溶的包衣)、在口腔中迅速崩解的片剂或薄膜/扁剂(oblate)、薄膜/冻干剂、胶囊剂(例如硬明胶胶囊剂或软明胶胶囊剂)、糖衣片剂、颗粒剂、丸剂、粉剂、乳剂、悬浮剂、气雾剂或溶液剂。
肠胃外给药可在避开吸收步骤的情况下进行(例如通过静脉内、动脉内、心内、椎管内或腰髓内的途径)或在包括吸收的情况下进行(例如通过肌内、皮下、皮内、经皮或腹膜内的途径)。适于肠胃外给药的给药形式包括以溶液剂、悬浮剂、乳剂、冻干剂或无菌粉剂形式注射和输液的制剂。
对于其他的给药途径,合适的实例为可吸入药物形式(包括粉末吸入剂、雾化剂)、滴鼻剂、溶液剂或喷雾剂;用于舌、舌下或颊给药的片剂、薄膜/扁剂或胶囊剂;栓剂;耳用或眼用制剂;阴道胶囊剂;水性悬浮剂(洗剂、振荡合剂(shaking mixture))、亲脂性悬浮剂;软膏剂;乳膏(cream);经皮治疗系统(例如贴剂);乳剂;糊剂;泡沫剂;洒粉剂(sprinklingpowder);植入物或支架。
优选口服或肠胃外给药,尤其是口服给药。
本发明的化合物可转化成所提及的给药形式。这可用本身已知的方式通过与惰性的、无毒的、药学上合适的助剂混合来完成。这些赋形剂包括载体(例如微晶纤维素、乳糖、甘露醇)、溶剂(例如液体聚乙二醇)、乳化剂和分散剂或润湿剂(例如十二烷基硫酸钠、聚氧脱水山梨糖醇油酸酯)、粘合剂(例如聚乙烯吡咯烷酮)、合成聚合物和天然聚合物(例如白蛋白)、稳定剂(例如抗氧化剂,例如抗坏血酸)、着色剂(例如无机颜料,例如氧化铁)以及调味剂(flavour)和/或气味矫正剂(odour correctant)。
总的来说,已发现,有利的是,在肠胃外给药的情况下,为达到有效的结果,给药量为约0.001至1mg/kg体重,优选约0.01至0.5mg/kg体重。在口服给药的情况下,剂量为约0.001至2mg/kg体重,优选约0.001至1mg/kg体重。
然而,在一些情况下,可能需要偏离所述量,具体随着体重、给药途径、对活性化合物的个体响应、制剂的性质以及给药时间或给药间隔变化。因此,在一些情况下,小于上述最小量可能是足够的,而在其他情况下,必须超过所提及的上限。在更大量给药的情况下,将它们分成一天内的几个单独的剂量是可取的。
以下工作实施例说明了本发明。本发明不限于所述实施例。
除非另有说明,以下试验和实施例中的百分比为重量百分比;份数为重量份数。液体/液体溶液的溶剂比、稀释比和浓度数据在每种情况下基于体积计。
A.实施例
缩写和首字母缩略词:
LC/MS和HPLC方法:
方法1(LC-MS):
仪器:具有Waters UPLC Acquity的Micromass Quattro Premier;柱:ThermoHypersil GOLD 1.9μ50×1mm;流动相A:1l水+0.5ml50%的甲酸,流动相B:1l乙腈+0.5ml50%浓度的甲酸;梯度:0.0min90%A→0.1min 90%A→1.5min 10%A→2.2min 10%A;柱温箱:50℃;流速:0.33ml/min;UV检测:210nm。
方法2(LC-MS):
仪器:Waters ACQUITY SQD UPLC系统;柱:Waters Acquity UPLC HSS T3 1.8μ50×1mm;流动相A:1l水+0.25ml 99%的甲酸,流动相B:1l乙腈+0.25ml 99%浓度的甲酸;梯度:0.0min 90%A→1.2min 5%A→2.0min 5%A;柱温箱:50℃;流速:0.40ml/min;UV检测:210-400nm。
方法3(LC-MS):
仪器:具有Waters UPLC Acquity的Micromass Quattro Premier;柱:ThermoHypersil GOLD 1.9μ50×1mm;流动相A:1l水+0.5ml50%的甲酸,流动相B:1l乙腈+0.5ml50%浓度的甲酸;梯度:0.0min97%A→0.5min 97%A→3.2min 5%A→4.0min 5%A;柱温箱:50℃;流速:0.3ml/min;UV检测:210nm。
方法4(LC-MS):
MS仪器:Waters(Micromass)QM;HPLC仪器:Agilent 1100系列;柱:AgilentZORBAX Extend-C18 3.0×50mm 3.5微米;流动相A:1l水+0.01mol碳酸铵,流动相B:1l乙腈;梯度:0.0min 98%A→0.2min 98%A→3.0min 5%A→4.5min 5%A;柱温箱:40℃;流速:1.75ml/min;UV检测:210nm。
方法5(LC-MS):
仪器:Waters ACQUITY SQD UPLC系统;柱:Waters Acquity UPLC HSS T3 1.8μ30×2mm;流动相A:1l水+0.25ml 99%的甲酸,流动相B:1l乙腈+0.25ml 99%浓度的甲酸;梯度:0.0min 90%A→1.2min 5%A→2.0min 5%A;柱温箱:50℃;流速:0.60ml/min;UV检测:208-400nm。
方法6(GC-MS):
仪器:Thermo Scientific DSQII,Thermo Scientific Trace GC Ultra;柱:Restek RTX-35MS,15m×200μm×0.33μm;氦气恒定流速:1.20ml/min;柱温箱:60℃;入口:220℃;梯度:60℃,30℃/min→300℃(保持3.33min)。
除非另有说明,以下试验和实施例中的百分比为重量百分比;份数为重量份数。液体/液体溶液的溶剂比、稀释比和浓度数据在每种情况下基于体积计。
在以下段落中报告的1H NMR谱中的质子信号的多重性代表在每种情况下观察到的信号形式,并未考虑任何高阶信号现象。在所有1H NMR谱数据中,化学位移δ以ppm表示。
此外,起始物料、中间体和工作实例可以水合物的形式存在。没有水含量的定量测定。在某些情况下,水合物可影响1H NMR谱,并且可能移动和/或显著加宽1H NMR中的水信号。
在1H NMR谱中,化学体系“2-甲基咪唑并[1,2-a]吡啶”的甲基以单峰形式出现(通常在DMSO-d6中并且在2.40-2.60ppm的范围内)且本身是可清楚识别的,被溶剂信号重叠或完全在溶剂的信号下。在所述1H NMR谱中,可以假定存在该信号。
当本发明的化合物用制备型HPLC通过上述方法(其中洗脱剂包含添加剂,例如三氟乙酸、甲酸或氨)进行纯化时,如果本发明的化合物包含足够碱性或酸性的官能度,则本发明的化合物可以盐形式(例如作为三氟乙酸盐、甲酸盐或铵盐)获得。这样的盐可通过本领域技术人员已知的各种方法转化成相应的游离碱或酸。
在下文所述的本发明的合成中间体和工作实例的情况下,以相应的碱或酸的盐的形式说明的任何化合物通常是准确化学计量组成未知的盐,如通过各自的制备和/或纯化方法获得。因此,在这类盐的情况下,除非更具体地说明,名称和结构式的附加项,如“盐酸盐”、“三氟乙酸盐”、“钠盐”或“x HCl”、“x CF3COOH”、“x Na+”不应理解为具有化学计量意义,而是对其中存在的成盐组分仅具有描述特征。
如果合成中间体或工作实例或其盐通过所述制备和/或纯化方法以化学计量组成未知的溶剂合物例如水合物的形式(如果它们具有确定类型)获得,则这相应地适用。
起始物料和中间体:
实施例1A
5-氯-2-硝基吡啶-3-醇
在冰冷却下,将30g 5-氯吡啶-3-醇(232mmol,1当量)溶解于228ml浓硫酸中,并在0℃下缓慢加入24ml浓硝酸。将反应加热至室温,搅拌过夜,然后搅拌加入到冰/水混合物中并再搅拌30min。将固体滤出,用冷水洗涤并风干。得到33g(理论值的82%)标题化合物,其无需进一步纯化即用于下一反应。
LC-MS(方法2):Rt=0.60min
MS(ESneg):m/z=172.9/174.9(M-H)-
1H-NMR(400MHz,DMSO-d6):δ=7.71(d,1H);8.10(d,1H);12.14(br.1H)。
实施例2A
5-氯-3-[(2,6-二氟苄基)氧基]-2-硝基吡啶
首先将33g 5-氯-2-硝基吡啶-3-醇(实施例1A;189mmol,1当量)和61.6g碳酸铯(189mmol,1当量)加入到528ml DMF中,加入40.4g 2,6-二氟苄溴(189mmol,1当量),并将混合物在室温下搅拌过夜。将反应混合物搅拌加入到水/1N盐酸水溶液中。将固体滤出,用水洗涤并风干。得到54.9g(理论值的97%)标题化合物。
1H-NMR(400MHz,DMSO-d6):δ=5.46(s,2H);7.22(t,2H);7.58(q,1H);8.28(d,1H);8.47(d,1H)。
实施例3A
5-氯-3-[(2,6-二氟苄基)氧基]吡啶-2-胺
首先将59.7g 5-氯-3-[(2,6-二氟苄基)氧基]-2-硝基吡啶(实施例2A;199mmol,1当量)加入到600ml乙醇中,加入34.4g铁粉(616mmol,3.1当量),并将混合物加热至回流。缓慢滴加152ml浓盐酸,并将混合物在回流下再沸腾30min。将反应混合物冷却并搅拌加入到冰/水混合物中。使用乙酸钠将所得混合物调节至pH 5。将固体滤出,用水洗涤并风干,然后在减压下在50℃下干燥。得到52.7g(理论值的98%)标题化合物。
LC-MS(方法2):Rt=0.93min
MS(ESpos):m/z=271.1/273.1(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=5.14(s,2H);5.82(br.s,2H);7.20(t,2H);7.35(d,1H);7.55(q,1H);7.56(d,1H)。
实施例4A
6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸乙酯
首先将40g 5-氯-3-[(2,6-二氟苄基)氧基]吡啶-2-胺(实施例3A;147.8mmol,1当量)加入到800ml乙醇中,加入30g粉末状分子筛和128g 2-氯乙酰乙酸乙酯(739mmol,5当量),并将混合物在回流下加热过夜。将反应混合物浓缩,并将残余物溶于乙酸乙酯中并过滤。将乙酸乙酯相用水洗涤,干燥,过滤并浓缩。得到44g(理论值的78%)标题化合物。
LC-MS(方法2):Rt=1.27min
MS(ESpos):m/z=381.2/383.2(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.36(t,3H);2.54(s,3H;被DMSO信号隐藏);4.37(q,2H);5.36(s,2H);7.26(t,2H);7.38(d,1H);7.62(q,1H);8.92(d,1H)。
实施例5A
6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸
将44g 6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸乙酯(实施例4A;115mmol,1当量)溶于550ml THF和700ml甲醇中,加入13.8g氢氧化锂(溶于150ml水中;577mmol,5当量),并将混合物在室温下搅拌过夜。加入1N盐酸水溶液,并将混合物在减压下浓缩。将所得到的固体滤出并用水洗涤。得到34g(理论值的84%)标题化合物。
LC-MS(方法1):Rt=1.03min
MS(ESpos):m/z=353.0/355.0(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=2.54(s,3H;被DMSO信号重叠);5.36(s,2H);7.26(t,2H);7.34(d,1H);7.61(q,1H);8.99(d,1H);13.36(br.s,1H)。
实施例6A
rac-2-氨基-3-氟-2-甲基丙腈
标题化合物由以下文献获知:
1)McConathy,J.等人,Journal of Medicinal Chemistry 2002,45,2240-2249。
2)Bergmann,E.D.等人,Journal of the Chemical Society 1963,3462-3463。
其他方法:
首先将1.0g(0.94ml;13.15mmol)氟丙酮加入到11ml 2N氨的甲醇溶液中。在室温下,依次加入721mg(14.72mmol)氰化钠和788mg(14.72mmol)氯化铵,并将混合物在回流下搅拌2小时。将反应溶液冷却,过滤并用二氯甲烷洗涤。固体从母液中沉淀出来,将其滤出。将二氯甲烷和甲醇在标准压力下从母液中蒸馏出。得到1.32g目标化合物(理论值的89%,纯度约90%)。将产物无需进一步纯化即用于下一反应。
GC-MS(方法6):Rt=1.64min
MS(EIpos):m/z=87(M-CH3)+
实施例7A
rac-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯
向于29ml THF/水(9/1)中的来自实施例6A的1.34g(11.83mmol,纯度约90%)rac-2-氨基-3-氟-2-甲基丙腈中加入5.07g(36.67mmol)碳酸钾。在0℃下,缓慢滴加1.69ml(11.83mmol)氯甲酸苄酯,并将反应混合物在室温下搅拌过夜。将溶剂轻轻倒出,并将水相用THF萃取两次,然后将THF轻轻倒出。将合并的有机相用硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯梯度)分离,并将产物级分在旋转蒸发仪上浓缩。得到1.89g目标化合物(理论值的66%,纯度97%)。
LC-MS(方法2):Rt=0.89min
MS(ESpos):m/z=237(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.58(d,3H),4.47-4.78(m,2H),5.10(s,2H),7.30-7.43(m,5H),8.34(br.s,1H)。
实施例8A
ent-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例7A的3.0g(12.69mmol)rac-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AY-H,5μm,250×20mm,流动相:80%异己烷,20%异丙醇,流速:15ml/min;40℃,检测:220nm]上分离成对映异构体。
对映异构体A:产量:1.18g(>99%ee)
Rt=5.37min[Daicel Chiralcel AY-H,5μm,250×4.6mm;流动相:70%异己烷,30%2-丙醇;流速1.0ml/min;40℃;检测:220nm]。
实施例9A
ent-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例7A的3.0g(12.69mmol)rac-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AY-H,5μm,250×20mm,流动相:80%异己烷,20%异丙醇,流速:15ml/min;40℃,检测:220nm]上分离成对映异构体。
对映异构体B:产量:1.18g(>99%ee)
Rt=6.25min[Daicel Chiralcel AY-H,5μm,250×4.6mm;流动相:70%异己烷,30%2-丙醇;流速1.0ml/min;40℃;检测:220nm]。
实施例10A
rac-(1-氨基-3-氟-2-甲基丙-2-基)氨基甲酸苄酯
在氩气下,将1.55g雷尼镍(水性浆液)加入到于14.9ml 7N氨的甲醇溶液中的来自实施例7A的1.2g(5.08mmol)rac-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯中,并将混合物在约25巴的氢气压力和室温下氢化24小时。将反应混合物过滤通过硅藻土,用甲醇洗涤并浓缩。得到1.2g目标化合物(理论值的98%)。
LC-MS(方法2):Rt=0.49min
MS(ESpos):m/z=241(M+H)+
实施例11A
ent-(1-氨基-3-氟-2-甲基丙-2-基)氨基甲酸苄酯(对映异构体A)
在氩气下,将1.55g雷尼镍(水性浆液)加入到于14.9ml 7N氨的甲醇溶液中的来自实施例8A的1.2g(5.08mmol)ent-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯(对映异构体A)中,并将混合物在约25巴的氢气压力和室温下氢化24小时。将反应混合物过滤通过硅藻土,用甲醇洗涤并浓缩。得到700mg目标化合物(理论值的57%,纯度约85%)。
LC-MS(方法2):Rt=0.52min
MS(ESpos):m/z=241(M+H)+
实施例12A
ent-(1-氨基-3-氟-2-甲基丙-2-基)氨基甲酸苄酯(对映异构体B)
在氩气下,将1.55g雷尼镍(水性浆液)加入到于14.9ml 7N氨的甲醇溶液中的来自实施例9A的1.2g(5.08mmol)ent-(2-氰基-1-氟丙-2-基)氨基甲酸苄酯(对映异构体B)中,并将混合物在约25巴的氢气压力和室温下氢化24小时。将反应混合物过滤通过硅藻土,用甲醇洗涤并浓缩。得到1.2g目标化合物(理论值的98%,纯度约85%)。
LC-MS(方法2):Rt=0.50min
MS(ESpos):m/z=241(M+H)+
实施例13A
rac-2-氨基-5,5,5-三氟-2-甲基戊腈
首先将8.0g(57.1mmol)5,5,5-三氟戊-2-酮[CAS登记号:1341078-97-4;市售,或者甲基酮可通过本领域技术人员已知的文献方法制备,例如a)由4,4,4-三氟丁醛根据Y.Bai等人Angewandte Chemie2012,51,4112-4116;K.Hiroi等人Synlett 2001,263-265;K.Mikami等人1982Chemistry Letters,1349-1352经两阶段制备;b)或由4,4,4-三氟丁酸根据A.A.Wube等人Bioorganic and Medicinal Chemistry 2011,19,567-579;G.M.Rubottom等人Journal of Organic Chemistry 1983,48,1550-1552;T.Chen等人Journal of Organic Chemistry 1996,61,4716-4719制备。产物可通过蒸馏或色谱法进行分离。]加入到47.8ml 2N氨的甲醇溶液中,在室温下加入3.69g(75.4mmol)氰化钠和4.03g(75.4mmol)氯化铵,并将混合物在回流下搅拌4小时。将反应混合物冷却,加入乙醚并将存在的固体滤出。将溶剂在标准压力下从滤液中蒸馏出。得到作为残余物的8.7g标题化合物(理论值的92%),其无需进一步纯化即用于后续阶段中。
GC-MS(方法6):Rt=1.90min
MS(ESpos):m/z=151(M-CH3)+
实施例14A
rac-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯
首先将来自实施例13A的8.7g(52.36mmol)rac-2-氨基-5,5,5-三氟-2-甲基戊腈加入到128ml四氢呋喃/水=9/1中,并加入22.43g(162.3mmol)碳酸钾。在0℃下,缓慢滴加8.93g(52.36mmol)氯甲酸苄酯。然后将混合物在搅拌下逐渐温热至室温,并在室温下搅拌过夜。将上清液溶剂轻轻倒出,将残余物用四氢呋喃搅拌两次,每次使用100ml四氢呋喃,然后每次将上清液溶剂轻轻倒出。将合并的有机相浓缩,并将粗产物通过硅胶色谱法(流动相:环己烷/乙酸乙酯梯度9/1至4/1)纯化。得到11.14g标题化合物(理论值的68%)。
LC-MS(方法2):Rt=1.01min
MS(ESpos):m/z=301(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.58(s,3H),2.08-2.21(m,2H),2.24-2.52(m,2H),5.09(s,2H),7.29-7.41(m,5H),8.17(br.s,1H)。
实施例15A
ent-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例14A的11.14g rac-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AZ-H,5μm,SFC,250×50mm,流动相:94%二氧化碳,6%甲醇,流速:200ml/min,温度:38℃,压力:135巴;检测:210nm]上分离成对映异构体。
对映异构体A:4.12g(约79%ee)
Rt=1.60min[SFC,Daicel Chiralpak AZ-H,250×4.6mm,5μm,流动相:90%二氧化碳,10%甲醇,流速:3ml/min,温度:30℃,检测:220nm]。
LC-MS(方法2):Rt=1.01min
MS(ESpos):m/z=301(M+H)+
实施例16A
ent-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例14A的11.14g rac-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AZ-H,5μm,SFC,250×50mm,流动相:94%二氧化碳,6%甲醇,流速:200ml/min,温度:38℃,压力:135巴;检测:210nm]上分离成对映异构体。
对映异构体B:4.54g(约70%ee,纯度约89%)
Rt=1.91min[SFC,Daicel Chiralpak AZ-H,250×4.6mm,5μm,流动相:90%二氧化碳,10%甲醇,流速:3ml/min,温度:30℃,检测:220nm]。
LC-MS(方法2):Rt=1.01min
MS(ESpos):m/z=301(M+H)+
实施例17A
ent-(1-氨基-5,5,5-三氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例15A的4.12g(13.17mmol)ent-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯(对映异构体A)溶于39ml 7N氨的甲醇溶液中,并在氩气下加入4g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化过夜。再加入1g雷尼镍(50%的水性浆液),并将反应混合物在高压釜中在20-30巴下氢化5h。将反应混合物过滤通过硅藻土,用甲醇冲洗并浓缩。得到3.35g(理论值的56%;纯度约67%)目标化合物,其无需进一步纯化即用于后续阶段中。
LC-MS(方法5):Rt=1.68min
MS(ESpos):m/z=305(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.13(s,3H),1.40(br.s,2H),1.70-1.80(m,1H),1.83-1.95(m,1H),2.08-2.2(m,2H),4.98(s,2H),6.85(br.s,1H),7.28-7.41(m,5H)。
实施例18A
ent-(1-氨基-5,5,5-三氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例16A的4.54g(13.45mmol;纯度约89%)ent-(2-氰基-5,5,5-三氟戊-2-基)氨基甲酸苄酯(对映异构体B)溶于39ml 7N氨的甲醇溶液中,并在氩气下加入5g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化3h。将反应混合物过滤通过硅藻土,用甲醇冲洗并浓缩。得到4.20g(理论值的97%;纯度约95%)目标化合物,其无需进一步纯化即用于后续阶段中。
LC-MS(方法4):Rt=2.19min
MS(ESpos):m/z=305(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.13(s,3H),1.40(br.s,2H),1.69-1.80(m,1H),1.83-1.96(m,1H),2.07-2.22(m,2H),4.98(s,2H),6.85(br.s,1H),7.27-7.40(m,5H)。
实施例19A
rac-2-[(二苯基亚甲基)氨基]-4-氟丁腈
首先将16.5g(74.91mmol)[(二苯基亚甲基)氨基]乙腈加入到495ml无水THF中,并在氩气下,在-78℃下,加入35.96ml(89.89mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下搅拌15min。随后,将反应溶液升温至0℃。将13.03g(74.91mmol)1-碘-2-氟乙烷滴加至反应溶液中,将其在0℃下再搅拌15min。在0℃下,向反应溶液中首先加入水,然后加入乙酸乙酯,并将混合物用饱和氯化钠水溶液洗涤。将水相用乙酸乙酯萃取两次。将合并的有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:二氯甲烷/环己烷=1/1至2/1)纯化。得到18.7g目标化合物(理论值的80%,纯度85%)。
LC-MS(方法3):Rt=2.42min
MS(ESpos):m/z=267(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=2.13-2.41(m,2H),4.40(t,1H),4.43-4.71(m,2H),7.25-7.30(m,2H),7.33-7.63(m,8H)。
实施例20A
rac-2-[(二苯基亚甲基)氨基]-4,4-二氟丁腈
首先将18g(81.72mmol)[(二苯基亚甲基)氨基]乙腈加入到500ml无水THF中,并在氩气下,在-78℃下,加入39.22ml(98.06mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下搅拌15min。随后,将反应溶液升温至0℃。将17.25g(89.89mmol)1,1-二氟-2-碘乙烷滴加至反应溶液中,将其在0℃下再搅拌15min。在0℃下,向反应溶液中首先加入水,然后加入乙酸乙酯,并将混合物用半饱和氯化钠水溶液洗涤三次。将合并的水相用乙酸乙酯萃取两次。将合并的有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:二氯甲烷/环己烷=1/1)纯化。得到13.57g目标化合物(理论值的49%,纯度84%)。
LC-MS(方法3):Rt=2.48min
MS(ESpos):m/z=285(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=2.53-2.61(m,2H;与溶剂峰部分叠加),4.50(t,1H),6.08-6.41(m,1H),7.23-7.33(m,2H),7.38-7.47(m,2H),7.49-7.67(m,6H)。
实施例21A
rac-2-[(二苯基亚甲基)氨基]-5-氟戊腈
首先将18g(81.72mmol)[(二苯基亚甲基)氨基]乙腈加入到500ml无水THF中,并在氩气下,在-78℃下,加入39.22ml(98.06mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下再搅拌15min。随后,将反应溶液升温至0℃并将16.9g(89.89mmol)1-氟-3-碘丙烷滴加至反应溶液中,将其在0℃下再搅拌15min。在0℃下,加入水,然后加入乙酸乙酯,并将混合物用饱和氯化钠水溶液洗涤。将水相用乙酸乙酯萃取两次。将合并的有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:甲苯100%,用二氯甲烷/环己烷=1/1至2/1再次纯化)纯化。得到16.73g目标化合物(理论值的73%)。
LC-MS(方法3):Rt=2.50min
MS(ESpos):m/z=281(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.66-1.85(m,2H),1.87-2.00(m,2H),4.26-4.41(m,2H),4.43-4.55(m,1H),7.20-7.33(m,2H),7.38-7.48(m,2H),7.48-7.63(m,6H)。
实施例22A
rac-2-[(二苯基亚甲基)氨基]-4-氟-2-甲基丁腈
在-78℃和氩气下,向来自实施例19A的19.94g(63.64mmol,85%纯度)rac-2-[(二苯基亚甲基)氨基]-4-氟丁腈于421ml无水THF中的初始进料中加入25.71ml(64.28mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下再搅拌10min。随后,在-78℃下,将36.1g(254.57mmol)碘甲烷加入到反应溶液中。将反应混合物经4.5h逐渐升至0℃。在0℃下,首先加入水,然后加入乙酸乙酯,并将混合物用饱和氯化钠水溶液洗涤两次。将有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯=15/1)纯化。得到17.2g目标化合物(理论值的78%,纯度81%)。
LC-MS(方法3):Rt=2.46min
MS(ESpos):m/z=281(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.65-1.67(s,3H),2.30-2.47(m,2H),4.55-4.84(m,2H),7.27-7.32(m,2H),7.37-7.42(m,2H),7.43-7.52(m,6H)。
实施例23A
rac-2-[(二苯基亚甲基)氨基]-4,4-二氟-2-甲基丁腈
在-78℃和氩气下,向来自实施例20A的13.07g(38.62mmol)rac-2-[(二苯基亚甲基)氨基]-4,4-二氟丁腈于255ml无水THF中的初始进料中加入15.6ml(39.0mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下再搅拌10min。随后,在-78℃下,将22.6g(154.46mmol)碘甲烷加入到反应溶液中。将反应混合物经3.5h逐渐升至0℃。在0℃下,首先加入水,然后加入乙酸乙酯,并将混合物用饱和氯化钠水溶液洗涤两次。将有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯=15/1)纯化。得到11.4g目标化合物(理论值的91%,纯度92%)。
LC-MS(方法3):Rt=2.52min
MS(ESpos):m/z=299(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.67(s,3H),2.55-2.77(m,2H),6.14-6.48(m,1H),7.28-7.34(m,2H),7.36-7.44(m,2H),7.44-7.54(m,6H)。
实施例24A
rac-2-[(二苯基亚甲基)氨基]-5-氟-2-甲基戊腈
在-78℃和氩气下,向来自实施例21A的16.73g(59.68mmol)rac-2-[(二苯基亚甲基)氨基]-5-氟戊腈于394ml无水THF中的初始进料中加入24.11ml(60.27mmol)正丁基锂(2.5N,在己烷中),并将混合物在-78℃下再搅拌10min。随后,在-78℃下,将34.93g(238.70mmol)碘甲烷加入到反应溶液中。将反应混合物经4.5h逐渐升至0℃。在0℃下,首先加入水,然后加入乙酸乙酯,并将混合物用饱和氯化钠水溶液洗涤两次。将有机相经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯=15/1)纯化。得到18.94g目标化合物(理论值的95%,纯度88%)。
LC-MS(方法3):Rt=2.55min
MS(ESpos):m/z=295(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.62(s,3H),1.73-1.90(m,2H),1.94-2.03(m,1H),2.04-2.18(m,1H),4.47(t,1H),4.58(t,1H),7.23-7.33(m,2H),7.35-7.43(m,2H),7.44-7.56(m,6H)。
实施例25A
rac-2-氨基-4-氟-2-甲基丁腈盐酸盐
将来自实施例22A的17.45g(50.45mmol;81%纯度)rac-2-[(二苯基亚甲基)氨基]-4-氟-2-甲基丁腈溶于235.6ml四氢呋喃和9.1ml水中,加入111ml(55.46mmol)氯化氢溶液(0.5N,在乙醚中)并将混合物在室温下搅拌过夜。然后加入25.21ml(50.42mmol)氯化氢溶液(2N,在乙醚中),并将混合物浓缩。将分离出的粗产物无需进一步纯化而直接进一步反应。
LC-MS(方法3):Rt=0.22min
MS(ESpos):m/z=117(M-HCl+H)+
实施例26A
rac-(2-氰基-4-氟丁-2-基)氨基甲酸苄酯
首先将来自实施例25A的粗产物rac-2-氨基-4-氟-2-甲基丁腈盐酸盐加入到165ml四氢呋喃/水(1:1)中,并加入28.57g(206.71mmol)碳酸钾和9.46g(55.46mmol)氯甲酸苄酯。将反应混合物在室温下搅拌过夜。再将1.72g(10.1mmol)氯甲酸苄酯加入到反应中,并将混合物在室温下再搅拌2h。然后,进行相分离,并将水相用乙酸乙酯萃取两次。将合并的有机相用饱和氯化钠水溶液洗涤一次,然后经硫酸钠干燥,过滤和浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯梯度20/1至5/1)纯化。得到5.04g目标化合物(经两个步骤,理论值的38%,)。
LC-MS(方法3):Rt=1.95min
MS(ESpos):m/z=251(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.59(s,3H),2.20-2.43(m,2H),4.55(t,1H),4.67(t,1H),5.08(s,2H),7.28-7.45(m,5H),8.12(br.s,1H)。
实施例27A
rac-2-氨基-4,4-二氟-2-甲基丁腈盐酸盐
将来自实施例23A的10.84g(33.43mmol;92%纯度)rac-2-[(二苯基亚甲基)氨基]-4,4-二氟-2-甲基丁腈溶于156ml四氢呋喃和6ml水中,加入73.5ml(36.77mmol)氯化氢溶液(0.5N,在乙醚中),并将混合物在室温下搅拌过夜。然后将16.71ml(33.43mmol)氯化氢溶液(2N,在乙醚中)加入到反应溶液中,并将混合物浓缩。将分离出的粗产物无需进一步纯化而直接进一步反应。
LC-MS(方法3):Rt=0.32min
MS(ESpos):m/z=135(M-HCl+H)+
实施例28A
rac-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯
首先将来自实施例27A的粗产物rac-2-氨基-4,4-二氟-2-甲基丁腈盐酸盐加入到109ml四氢呋喃/水(1:1)中,加入18.94g(137.06mmol)碳酸钾和6.27g(36.77mmol)氯甲酸苄酯,并将混合物在室温下搅拌过夜。再将1.14g(6.69mmol)氯甲酸苄酯加入到反应中,并将混合物在室温下再搅拌2h。然后进行相分离,并将水相用乙酸乙酯萃取两次。将合并的有机相用饱和氯化钠水溶液洗涤一次,然后经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯梯度20/1至5/1)纯化。得到7.68g目标化合物(经两个步骤,理论值的61%,纯度71%)。
LC-MS(方法3):Rt=2.04min
MS(ESpos):m/z=269(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.65(s,3H),2.51-2.65(m,2H),5.10(s,2H),6.08-6.41(m,1H),7.27-7.44(m,5H),8.24(br.s,1H)。
实施例29A
rac-2-氨基-5-氟-2-甲基戊腈盐酸盐
将来自实施例24A的18.94g(56.62mmol;88%纯度)rac-2-[(二苯基亚甲基)氨基]-5-氟-2-甲基戊腈溶于264.6ml四氢呋喃和10.2ml水中,加入124.6ml(62.28mmol)氯化氢溶液(0.5N,在乙醚中),并将混合物在室温下搅拌过夜。然后加入28.3ml(56.62mmol)氯化氢溶液(2N,在乙醚中),并将混合物浓缩。将分离出的粗产物无需进一步纯化而直接进一步反应。
LC-MS(方法3):Rt=0.25min
MS(ESpos):m/z=131(M-HCl+H)+
实施例30A
rac-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯
首先将来自实施例29A的粗产物rac-2-氨基-5-氟-2-甲基戊腈盐酸盐加入到185ml四氢呋喃/水(1:1)中,加入32.09g(232.18mmol)碳酸钾和10.63g(62.29mmol)氯甲酸苄酯,并将混合物在室温下搅拌过夜。再将1.93g(11.33mmol)氯甲酸苄酯加入到反应中,并将混合物在室温下再搅拌2h。然后进行相分离,并将水相用乙酸乙酯萃取两次。将合并的有机相用饱和氯化钠水溶液洗涤一次,然后经硫酸钠干燥,过滤并浓缩。将残余物通过硅胶色谱法(流动相:环己烷/乙酸乙酯梯度20/1至5/1)纯化。得到11.77g目标化合物(经两个阶段,理论值的72%,92%纯度)。
LC-MS(方法3):Rt=2.03min
MS(ESpos):m/z=265(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.55(s,3H),1.66-1.85(m,2H),1.86-2.04(m,2H),4.40(t,1H),4.52(t,1H),5.08(s,2H),7.28-7.44(m,5H),8.05(br.s,1H)。
实施例31A
ent-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例28A的7.68g(20.33mmol,纯度71%)rac-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AY-H,5μm,250×20mm,流动相:80%异己烷,20%异丙醇;流速:25ml/min;温度:22℃,检测210nm]上分离成对映异构体。
对映异构体A:产量:2.64g(>99%ee)
Rt=6.67min[Chiralpak AY-H,5μm,250×4.6mm;流动相:80%异己烷,20%异丙醇;流速:3ml/min;检测:220nm]。
实施例32A
ent-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例28A的7.68g(20.33mmol,纯度71%)rac-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:Daicel Chiralpak AY-H,5μm,250×20mm,流动相:80%异己烷,20%异丙醇;流速:25ml/min;温度:22℃,检测210nm]上分离成对映异构体。
对映异构体B:产量:2.76g(93%ee)
Rt=7.66min[Chiralpak AY-H,5μm,250×4.6mm;流动相:80%异己烷,20%异丙醇;流速:3ml/min;检测:220nm]。
实施例33A
ent-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例30A的11.77g(40.97mmol,纯度92%)rac-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:SFC Daicel Chiralpak AZ-H,5μm,250×30mm,流动相:90%CO2,10%甲醇,流速:100ml/min;温度:40℃,检测:210nm]上分离成对映异构体。
对映异构体A:产量:5.7g(>99%ee)
Rt=1.76min[SFC Chiralpak AZ-3,3μm,50×4.6mm;流动相:CO2/甲醇梯度(5%至60%甲醇);流速:3ml/min;检测:220nm]。
实施例34A
ent-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例30A的11.77g(40.97mmol,纯度92%)rac-(2-氰基-5-氟丁-2-基)氨基甲酸苄酯通过制备型分离在手性相[柱:SFC Daicel Chiralpak AZ-H,5μm,250×30mm,流动相:90%CO2,10%甲醇,流速:100ml/min;温度:40℃,检测:210nm]上分离成对映异构体。
对映异构体B:产量:5.0g(>99%ee)
Rt=1.97min[SFC Chiralpak AZ-3,3μm,50×4.6mm;流动相:CO2/甲醇梯度(5%至60%甲醇);流速:3ml/min;检测:220nm]。
实施例35A
ent-(1-氨基-4,4-二氟-2-甲基丁-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例31A的2.3g(8.57mmol)ent-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯(对映异构体A)溶于75ml 7N氨的甲醇溶液中,并在氩气下加入2.66g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化1.5h。将反应混合物过滤通过硅藻土,用甲醇和2N氨的甲醇溶液冲洗,并浓缩。得到2.23g目标化合物(理论值的94%)。
LC-MS(方法3):Rt=1.48min
MS(ESpos):m/z=273(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.19(s,3H),1.48(br.s,2H),2.08-2.40(m,2H),2.53-2.72(m,2H;与溶剂峰部分重叠),5.00(s,2H),5.90-6.23(m,1H),6.95(br.s,1H),7.25-7.41(m,5H)。
实施例36A
ent-(1-氨基-4,4-二氟-2-甲基丁-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例32A的2.76g(10.29mmol)ent-(2-氰基-4,4-二氟丁-2-基)氨基甲酸苄酯(对映异构体B)溶于90ml 7N氨的甲醇溶液中,并在氩气下加入3.19g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化1.5h。将反应混合物过滤通过硅藻土,用甲醇和2N氨的甲醇溶液冲洗,并浓缩。得到2.64g目标化合物(理论值的88%,纯度93%)。
LC-MS(方法3):Rt=1.49min
MS(ESpos):m/z=273(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.19(s,3H),1.48(br.s,2H),2.08-2.40(m,2H),2.53-2.73(m,2H;与溶剂峰部分重叠),5.00(s,2H),5.90-6.24(m,1H),6.95(br.s,1H),7.25-7.41(m,5H)。
实施例37A
ent-(1-氨基-5-氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体A)
将来自实施例33A的5.7g(21.57mmol)ent-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯(对映异构体A)溶于125ml 7N氨的甲醇溶液中,并在氩气下加入6.68g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化4.5h。将反应混合物过滤通过硅藻土,用甲醇和2N氨的甲醇溶液冲洗,并浓缩。得到5.22g目标化合物(理论值的77%,纯度85%)。
LC-MS(方法3):Rt=1.51min
MS(ESpos):m/z=269(M+H)+
实施例38A
ent-(1-氨基-5-氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体B)
将来自实施例34A的5.0g(18.92mmol)ent-(2-氰基-5-氟戊-2-基)氨基甲酸苄酯(对映异构体B)溶于110ml 7N氨的甲醇溶液中,并在氩气下加入5.86g雷尼镍(50%的水性浆液)。将反应混合物在高压釜中在20-30巴下氢化4.5h。将反应混合物过滤通过硅藻土,用甲醇和2N氨的甲醇溶液冲洗,并浓缩。得到4.6g目标化合物(理论值的84%,纯度93%)。
LC-MS(方法3):Rt=1.47min
MS(ESpos):m/z=269(M+H)+
实施例39A
rac-4-氟-2-甲基丁烷-1,2-二胺二盐酸盐
将来自实施例26A的1.00g(4.00mmol)rac-(2-氰基-4-氟丁-2-基)氨基甲酸苄酯溶于114ml乙醇/冰醋酸(1/1)中,并加入0.85g于活性碳上的钯(10%)。将反应混合物在高压釜中在30-50巴下氢化3h。将反应混合物过滤,将滤饼用乙醇冲洗,然后将滤液再次过滤通过微孔滤器。将滤液与10ml氯化氢溶液(2N,在乙醚中)混合,然后浓缩。得到1.04g目标化合物,其无需进一步纯化即用于后续阶段中。
LC-MS(方法3):Rt=0.19min
MS(ESpos):m/z=121(M-2HCl+H)+
实施例40A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-3-氟-2-甲基丙-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)
将来自实施例5A的150mg(0.43mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.7ml DMF中,加入178mg(0.47mmol)HATU和0.22ml(1.28mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。随后,加入来自实施例12A的133mg(0.47mmol,85%纯度)ent-(1-氨基-3-氟-2-甲基丙-2-基)氨基甲酸苄酯(对映异构体B)。将混合物在室温下搅拌过夜,然后通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到216mg标题化合物(理论值的63%;纯度86%)。
LC-MS(方法2):Rt=1.23min
MS(ESpos):m/z=575(M-TFA+H)+
实施例41A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5,5,5-三氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)
将来自实施例5A的150mg(0.43mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.7ml DMF中,加入178mg(0.47mmol)HATU和0.22ml(1.28mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。随后,加入来自实施例18A的150mg(0.47mmol,95%纯度)ent-(1-氨基-5,5,5-三氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体B)。将混合物在室温下搅拌过夜,然后通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到216mg标题化合物(理论值的79%)。
LC-MS(方法2):Rt=1.31min
MS(ESpos):m/z=639(M-TFA+H)+
实施例42A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5-氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体A)
将来自实施例5A的250mg(0.71mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.36ml DMF中,加入350mg(0.92mmol)HATU和0.62ml(3.54mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。随后,加入来自实施例37A的291mg(0.92mmol,85%纯度)ent-(1-氨基-5-氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体A)。30min后,加入水并将所得固体滤出并用水洗涤。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到397mg标题化合物(理论值的71%;纯度91%)。
LC-MS(方法2):Rt=1.21min
MS(ESpos):m/z=603(M-TFA+H)+
1H-NMR(500MHz,DMSO-d6):δ[ppm]=1.22(s,3H),1.52-1.75(m,3H),1.80-1.93(m,1H),2.53(s,3H;与溶剂峰叠加),3.49-3.61(m,2H),4.29-4.38(m,1H),4.39-4.51(m,1H),5.00(s,2H),5.37(s,2H),7.07-7.17(m,1H),7.20-7.38(m,8H),7.54-7.64(m,1H),7.90(t,1H),8.76(d,1H)。
实施例43A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5-氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)
将来自实施例5A的250mg(0.71mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.36ml DMF中,加入350mg(0.92mmol)HATU和0.62ml(3.54mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。随后,加入来自实施例38A的267mg(0.92mmol,93%纯度)ent-(1-氨基-5-氟-2-甲基戊-2-基)氨基甲酸苄酯(对映异构体B)。30min后,加入水并将所得固体滤出并用水洗涤。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到328mg标题化合物(理论值的61%;纯度94%)。
LC-MS(方法2):Rt=1.21min
MS(ESpos):m/z=603(M-TFA+H)+
实施例44A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-4,4-二氟-2-甲基丁-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体A)
将来自实施例5A的250mg(0.71mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.36ml DMF中,加入350mg(0.92mmol)HATU和0.62ml(3.54mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。然后加入来自实施例35A的256mg(0.92mmol)ent-(1-氨基-4,4-二氟-2-甲基丁-2-基)氨基甲酸苄酯(对映异构体A)。60min后,加入水并将所得固体滤出并用水洗涤。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到439mg标题化合物(理论值的86%)。
LC-MS(方法2):Rt=1.22min
MS(ESpos):m/z=607(M-TFA+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.29(s,3H),2.05-2.25(m,2H),2.53(s,3H;与溶剂峰重叠),3.54-3.62(m,2H;与溶剂峰重叠),5.01(s,2H),5.38(s,2H),5.98-6.29(m,1H),7.18-7.39(m,9H),7.54-7.64(m,1H),7.95(t,1H),8.74(d,1H)。
实施例45A
ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-4,4-二氟-2-甲基丁-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)
将来自实施例5A的250mg(0.71mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸溶于2.36ml DMF中,加入323mg(0.85mmol)HATU和0.62ml(3.54mmol)N,N-二异丙基乙胺,并将混合物在室温下搅拌20min。然后加入来自实施例36A的246mg(0.85mmol,93%纯度)ent-(1-氨基-4,4-二氟-2-甲基丁-2-基)氨基甲酸苄酯(对映异构体B)。30min后,加入水并将所得固体滤出并用水洗涤。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。得到431mg标题化合物(理论值的82%)。
LC-MS(方法2):Rt=1.21min
MS(ESpos):m/z=607(M-TFA+H)+
1H-NMR(500MHz,DMSO-d6):δ[ppm]=1.29(s,3H),2.06-2.24(m,2H),2.53(s,3H;与溶剂峰重叠),3.55-3.62(m,2H),5.01(s,2H),5.38(s,2H),6.00-6.29(m,1H),7.19-7.39(m,9H),7.55-7.64(m,1H),7.99(t,1H),8.74(d,1H)。
工作实施例:
实施例1
ent-N-(2-氨基-3-氟-2-甲基丙基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
将来自实施例40A的216mg(0.27mmol,纯度86%)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-3-氟-2-甲基丙-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)溶于7ml乙醇中,加入14mg于活性碳上的钯(10%),并将混合物在标准压力下氢化1小时。将反应溶液过滤通过微孔滤器,将滤饼用乙醇洗涤,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化两次。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到53mg目标化合物(理论值的43%)。
LC-MS(方法2):Rt=0.70min
MS(ESpos):m/z=441(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.04(s,3H),1.65(br.s,2H),2.55(s,3H;与溶剂峰重叠),3.24-3.39(m,2H;与溶剂峰重叠),4.08-4.14(m,1H),4.19-4.27(m,1H),5.35(s,2H),7.16-7.29(m,3H),7.55-7.65(m,1H),7.72-7.81(m,1H),8.75(d,1H)。
实施例2
ent-N-(2-氨基-5,5,5-三氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
将来自实施例41A的261mg(0.35mmol)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5,5,5-三氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)溶于9ml乙醇中,加入11mg于活性碳上的钯(10%),并将混合物在标准压力下氢化1.5小时。将反应溶液过滤通过微孔滤器,将滤饼用乙醇洗涤,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到105mg目标化合物(理论值的59%)。
LC-MS(方法2):Rt=0.80min
MS(ESpos):m/z=505(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.02(s,3H),1.47-1.61(m,4H),2.24-2.47(m,2H),2.53(s,3H;与溶剂峰叠加),3.18-3.28(m,2H),5.35(s,2H),7.17-7.29(m,3H),7.55-7.65(m,1H),7.81-7.92(m,1H),8.70(d,1H)。
实施例3
ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
将来自实施例42A的397mg(0.50mmol,纯度91%)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5-氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体A)溶于12.9ml乙醇中,加入16mg于活性碳上的钯(10%),并将混合物在标准压力下氢化1.5小时。借助微孔滤器将反应溶液过滤,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到133mg目标化合物(理论值的55%)。
LC-MS(方法2):Rt=0.71min
MS(ESpos):m/z=469(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.02(s,3H),1.30-1.42(m,2H),1.43-1.88(m,4H),2.53(s,3H;被溶剂峰叠加),3.17-3.30(m,2H),4.30-4.39(m,1H),4.42-4.52(m,1H),5.34(s,2H),7.18-7.30(m,3H),7.55-7.64(m,1H),7.78(br.s,1H),8.75(d,1H)。
实施例4
ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
将来自实施例43A的328mg(0.43mmol,纯度94%)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-5-氟-2-甲基戊-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)溶于11.1ml乙醇中,加入14mg于活性碳上的钯(10%),并将混合物在标准压力下氢化3小时。将反应溶液过滤通过硅藻土,将滤饼用乙醇洗涤,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到133mg目标化合物(理论值的63%)。
LC-MS(方法4):Rt=2.35min
MS(ESpos):m/z=469(M+H)+
1H-NMR(500MHz,DMSO-d6):δ[ppm]=1.01(s,3H),1.32-1.42(m,2H),1.45-1.83(m,4H),2.53(s,3H;被溶剂峰重叠),3.18-3.29(m,2H),4.32-4.39(m,1H),4.43-4.50(m,1H),5.34(s,2H),7.18-7.28(m,3H),7.56-7.63(m,1H),7.78(br.s,1H),8.75(d,1H)。
实施例5
ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
将来自实施例44A的439mg(0.61mmol)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-4,4-二氟-2-甲基丁-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体A)溶于15.6ml乙醇中,加入19mg于活性碳上的钯(10%),并将混合物在标准压力下氢化75min。将反应溶液过滤通过微孔滤器,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到152mg目标化合物(理论值的52%)。
LC-MS(方法2):Rt=0.75min
MS(ESpos):m/z=473(M+H)+
1H-NMR(400MHz,DMSO-d6):δ[ppm]=1.08(s,3H),1.70(br.s,2H),1.83-1.99(m,2H),2.53(s,3H;被溶剂峰重叠),3.20-3.35(m,2H;被溶剂峰重叠),5.34(s,2H),6.08-6.42(m,1H),7.18-7.29(m,3H),7.55-7.64(m,1H),7.82(t,1H),8.73(d,1H)。
实施例6
ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
将来自实施例45A的431mg(0.59mmol,纯度97%)ent-{1-[({6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-基}羰基)氨基]-4,4-二氟-2-甲基丁-2-基}氨基甲酸苄酯三氟乙酸盐(对映异构体B)溶于15.1ml乙醇中,加入19mg于活性碳上的钯(10%),并将混合物在标准压力下氢化75min。将反应溶液过滤通过微孔滤器,并将滤液浓缩。将残余物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用少量饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到149mg目标化合物(理论值的53%)。
LC-MS(方法2):Rt=0.74min
MS(ESpos):m/z=473(M+H)+
1H-NMR(500MHz,DMSO-d6):δ[ppm]=1.08(s,3H),1.70(br.s,2H),1.84-1.98(m,2H),2.53(s,3H;被溶剂峰重叠),3.22-3.32(m,2H;被溶剂峰重叠),5.34(s,2H),6.10-6.38(m,1H),7.18-7.28(m,3H),7.57-7.63(m,1H),7.82(t,1H),8.73(d,1H)。
实施例7
rac-N-(2-氨基-4-氟-2-甲基丁基)-6氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(外消旋体)
首先向来自实施例5A的200mg(0.57mmol)6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酸中加入于2.6ml DMF中的259mg(0.68mmol)HATU和0.40ml(2.27mmol)N,N-二异丙基乙胺,并将混合物搅拌20min。将来自实施例39A的311mg(1.20mmol,假定纯度约75%)rac-4-氟-2-甲基丁烷-1,2-二胺二盐酸盐于1.3ml DMF和0.59ml(3.40mmol)N,N-二异丙基乙胺中的溶液加入到第一反应混合物中,并将混合物在RT下搅拌0.5h。加入乙腈、水和TFA,并将产物通过制备型HPLC(RP18柱,流动相:乙腈/水梯度,其中加入0.1%TFA)纯化。将产物级分合并并浓缩。随后,将残余物溶于二氯甲烷和少量甲醇中,并用饱和碳酸氢钠水溶液洗涤两次。将水相用二氯甲烷萃取两次。将合并的有机相经硫酸钠干燥,过滤,浓缩并冻干。得到100mg目标化合物(理论值的38%)。
LC-MS(方法2):Rt=0.69min
MS(ESpos):m/z=455(M+H)+
1H-NMR(400MHz,DMSO-d6):δ=1.04(s,3H),1.58(br.s,2H),1.66–1.84(m,2H),2.56(s,3H),3.19-3.32(m,2H;与溶剂峰部分重叠),4.55-4.63(m,1H),4.66-4.73(m,1H),5.34(s,2H),7.17-7.28(m,3H),7.56-7.64(m,1H),7.72-7.83(m,1H),8.74(d,1H)。
实施例8
ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)
将来自实施例7的135mg(0.30mmol)rac-N-(2-氨基-4-氟-2-甲基丁基)-6氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺通过制备型分离在手性相[柱:Daicel Chiralpak IF,5μm,250×20mm,流动相:100%乙醇+0.2%二乙胺,流速:15ml/min,温度:45℃,检测:220nm]上分离成对映异构体。
将产物级分在干冰上收集,浓缩(浴温:30℃)并冻干。
对映异构体A:产量:50mg(>99%ee)
Rt=6.85min[Chiralpak AZ-H,5μm,250×4.6mm;流动相:100%乙醇+0.2%二乙胺;流速:1ml/min;检测:270nm]。
实施例9
ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)
将来自实施例7的135mg rac-N-(2-氨基-4-氟-2-甲基丁基)-6氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺通过制备型分离在手性相[柱:DaicelChiralpak IF,5μm,250×20mm,流动相:100%乙醇+0.2%二乙胺,流速:15ml/min,温度:45℃,检测:220nm]上分离成对映异构体。
将产物级分在干冰上收集,浓缩(浴温:30℃)并冻干。
对映异构体B:产量:50mg(96%ee)
Rt=9.80min[Chiralpak AZ-H,5μm,250×4.6mm;流动相:100%乙醇+0.2%二乙胺;流速:1ml/min;检测270nm]。
B.药理功效的评估
使用以下缩写:
ATP 三磷酸腺苷
Brij35 聚氧乙烯(23)月桂基醚
BSA 牛血清白蛋白
DTT 二硫苏糖醇
TEA 三乙醇胺
本发明化合物的药理作用可通过以下试验证明:
B-1.通过PPi检测来测量sGC酶活性
可溶性鸟苷酸环化酶(sGC)在受刺激时将GTP转化成cGMP和焦磷酸盐(PPi)。PPi借助WO 2008/061626中记载的方法来检测。在试验中产生的信号随着反应进行而增加,并且用作sGC酶活性的衡量标准。借助PPi参考曲线,酶可以已知方式表征,例如在转化速率、可刺激性或米氏(Michaelis)常数方面。
试验的实施
为了实施试验,首先将29μl酶溶液[0-10nM可溶性鸟苷酸环化酶(根据等人,Journal of Molecular Medicine 77(1999)14-23制备),在50mM TEA、2mM氯化镁、0.1%BSA(级分V)、0.005%Brij35中,pH 7.5]加入到微量培养板中,并加入1μl刺激剂溶液(0-10μM 3-吗啉代斯德酮亚胺(3-morpholinosydnonimine),SIN-1,Merck在DMSO中)。将微量培养板在RT下培养10min。然后,加入20μl检测混合物(1.2nM荧火虫荧光素酶(北美萤火虫(Photinus pyralis)荧光素酶,Promega)、29μM脱氢萤光素(根据Bitler&McElroy,Arch.Biochem.Biophys.72(1957)358制备)、122μM萤光素(Promega)、153μM ATP(Sigma)和0.4mM DTT(Sigma)在50mM TEA、2mM氯化镁、0.1%BSA(级分V)、0.005%Brij 35中,pH7.5)。通过加入20μl底物溶液(1.25mM 5’-三磷酸鸟苷(Sigma)在50mM TEA、2mM氯化镁、0.1%BSA(级分V)、0.005%Brij 35中,pH 7.5)启动酶反应,并在光度计中进行连续分析。
B-2.对重组鸟苷酸环化酶报道细胞系的作用
使用重组鸟苷酸环化酶报道细胞系测定本发明的化合物的细胞活性,如在F.Wunder等人,Anal.Biochem.339,104-112(2005)中所记载。
下表中示出了本发明化合物的代表性MEC值(MEC=最低有效浓度)(在一些情况下为各次测定的平均值):
表A
B-3.体外血管舒张作用
通过打击颈部将兔子打昏并放血。将主动脉取出,去除附着的组织并分成1.5mm宽的环,在预应力下,将所述环逐个地放入5ml器官浴槽中,所述浴槽含有37℃的用碳合气(carbogen)充气的克雷布斯-汉斯莱特(Krebs-Henseleit)溶液,所述溶液具有以下组成(各自以mM计):氯化钠:119;氯化钾:4.8;二水合氯化钙:1;七水合硫酸镁:1.4;磷酸二氢钾:1.2;碳酸氢钠:25;葡萄糖:10。用Statham UC2细胞测定收缩力,使用A/D转换器(DAS-1802HC,Keithley Instruments Munich)放大和数字化,并在线性记录仪上平行地记录。为了产生收缩,将苯肾上腺素以增加的浓度累积地加入浴槽中。几个对照循环后,将待研究的物质在每一个进一步的循环中每次以增加的剂量加入,并将收缩量与在最近的前一循环中获得的收缩量进行比较。这用于计算将对照值的量值减少50%所需的浓度(IC50值)。标准给药体积是5μl;浴槽溶液中的DMSO含量相当于0.1%。
B-4.麻醉大鼠的血压测量
用戊硫代巴比妥(100mg/kg腹膜内)将体重为300-350g的雄性Wistar大鼠麻醉。在气管切开术后,将导管引入股动脉以测量血压。将待试验的物质作为溶液剂通过管饲法口服给药或经股静脉静脉内给药(Stasch等人Br.J.Pharmacol.2002;135:344-355)。
B-5.无线电遥测测量清醒自发性高血压大鼠的血压
使用购自DATA SCIENCES INTERNATIONAL DSI,USA的市售遥测系统进行下文所述的对清醒大鼠的血压测量。
所述系统由3个主要组件组成:
植入式发射器(遥测发射器)
接收器(接收器),其经由多路转接器(DSI Data Exchange Matrix)连接到
数据采集计算机。
所述遥测系统可以连续记录清醒动物在它们的通常栖息地中的血压、心率和身体动作。
动物材料
研究在体重>200g的成年雌性自发性高血压大鼠(SHR Okamoto)上进行。购自Okamoto Kyoto School of Medicine,1963的SHR/NCrl是血压极大升高的雄性WistarKyoto大鼠与血压稍微升高的雌性大鼠的杂交种,且其在F13上移送至美国国立卫生研究院(U.S.National Institutes of Health)。
在发射器植入后,将实验动物单独圈养在3型Makrolon笼中。它们可自由摄取标准饲料和水。
实验室中的日/夜节律由室内照明在上午6:00和下午7:00改变。
发射器植入
在第一次实验使用之前至少14天,将所用的TA11PA-C40遥测发射器在无菌条件下手术植入到实验动物中。以此方式带有仪器的动物可在伤口愈合和植入物固定后重复使用。
为了植入,将禁食的动物用戊巴比妥(耐波他(Nembutal),Sanofi:50mg/kg腹膜内)麻醉,然后在其腹部的大面积上剃毛并消毒。在沿白线打开腹腔后,将所述系统的充满液体的测量导管在分叉点(bifurcation)上方沿颅骨(cranial)方向插入到降主动脉中并用组织胶(VetBonD TM,3M)固定。将发射器外壳在腹膜内固定至腹壁肌肉上,并将伤口逐层闭合。
在术后,给予抗生素(Tardomyocel COMP,Bayer,1ml/kg皮下)以预防感染。
物质和溶液
除非另有说明,将待研究的物质在每种情况下通过管饲法口服给予一组动物(n=6)。按照5ml/kg体重的给药体积,将试验物质溶解于合适的溶剂混合物中或悬浮在0.5%纤基乙酸钠(tylose)中。
将溶剂处理的动物组用作对照。
实验概述
将现有的遥测测量装置配置以用于24只动物。按实验编号(V年月日)记录每次实验。
对每一个生活在所述系统中的带有仪器的大鼠分配一个独立的接收天线(1010Receiver,DSI)。
植入的发射器可通过内置式磁开关从外部激活。在实验前将它们切换到发射。所发射的信号可通过数据采集系统(Dataquest TM A.R.T.for WINDOWS,DSI)在线检测并相应地进行处理。将数据在每种情况下储存在为此目的创建并带有实验编号的文件夹中。
在标准程序中,在每种情况下以下各项测量10秒:
收缩期血压(SBP)
舒张血压(DBP)
平均动脉压(MAP)
心率(HR)
活性(ACT)。
在计算机控制下以5分钟的间隔重复采集测量值。将得到的绝对值形式的源数据在图表中用当前测量的气压(Ambient Pressure Reference Moniotr;APR-1)进行校正并储存为单独的数据。其他技术细节在制造公司(DSI)的大量文件中给出。
除非另有说明,在实验当天的上午9:00给予试验物质。给药后,在24小时期间测量上述参数。
评价
在实验结束后,用分析软件(DATAQUEST TM A.R.T.TM ANALYSIS)将所采集的单独数据分类。在本文中,假定给药前2小时的时间点为空白值,因此所选择的数据集包括从实验当天上午7:00至第二天上午9:00的时间段。
通过测定平均值(15-分钟平均值)将数据在可预定义的时段内平滑并将其以文本文件的形式转移到存储介质上。将以此方式预分类并压缩的测量值转移到Excel模板中并制成表。实验的每一天,将得到的数据储存在带有实验编号的专用文件夹中。将结果和试验方案存储在按照编号分类的纸件形式的文件夹中。
文献:
Klaus Witte,Kai Hu,Johanna Swiatek,Claudia Müssig,Georg Ertl和Lemmer:Experimental heart failure in rats:effects on cardiovascular circadianrhythms and on myocardialβ-adrenergic signaling.Cardiovasc Res 47(2):203-405,2000;Kozo Okamoto:Spontaneous hypertension in rats.Int Rev Exp Pathol 7:227-270,1969;Maarten van den Buuse:Circadian Rhythms of Blood Pressure,HeartRate,and Locomotor Activity in Spontaneously Hypertensive Rats as MeasuredWith Radio-Telemetry.Physiology&Behavior 55(4):783-787,1994。
B-6.静脉给药和口服给药后药代动力学参数的测定
在雄性CD-1小鼠、雄性Wistar大鼠和雌性小猎犬中测定本发明的化合物的药代动力学参数。在小鼠和大鼠的情况下,静脉给药通过物种特异性的血浆/DMSO制剂进行,在狗的情况下,通过水/PEG400/乙醇制剂进行。在所有物种中,基于水/PEG400/乙醇制剂,通过管饲法进行溶解物质的口服给药。在将物质给药前,通过将硅胶导管插入右颈外静脉(Venajugularis externa)中而简化从大鼠中采血。手术在实验前至少一天进行,其中使用异氟醚麻醉并给予止痛剂(阿托品/卡布洛芬(rimadyl)(3/1)0.1ml皮下)。在包括物质给药后至少24小时至最多72小时的终端时间点的时间窗口内采血(通常多于10个时间点)。将血采集到肝素化管中。然后通过离心获得血浆;如果需要,将其储存在-20℃下直至进一步处理。
将内标物(其也可以是化学上不相关的物质)加到本发明化合物的样品、校准样品和限定物(qualifier)中,接着通过过量乙腈使蛋白质沉淀。添加与LC条件匹配的缓冲溶液,随后涡旋,接着在1000g下离心。通过LC-MS/MS使用C18反相柱和可变的流动相混合物对上清液进行分析。通过来自特定选择离子监测实验的萃取离子色谱图的峰高或峰面积对物质进行定量。
借助经验证的药代动力学计算程序,使用所测定的血浆浓度/时间图来计算药代动力学参数如AUC、Cmax、t1/2(终末半衰期)、F(生物利用度)、MRT(平均停留时间)和CL(清除率)。
由于物质定量是在血浆中进行的,因此为了能够相应地调节药代动力学参数,必须测定物质的血液/血浆分布。为此目的,在摇滚式混合器(rocking roller mixer)中将限定量的物质在所讨论物种的肝素化全血中培养20min。在1000g下离心后,测量并通过计算C血液/C血浆值之比确定血浆浓度(通过LC-MS/MS;见上文)。
B-7.代谢研究
为了确定本发明化合物的代谢特性,将它们与重组人细胞色素P450(CYP)酶、肝微粒体或来自各种动物物种(例如大鼠、狗)以及人类来源的原发新鲜肝细胞培养,以获得和比较关于尽可能完整的肝期I和肝期II代谢以及关于参与代谢的酶的信息。
将本发明的化合物以约0.1-10μM的浓度培养。为此,制备浓度为0.01-1mM的本发明化合物在乙腈中的储备液,然后以1:100稀释度吸移到培养混合物中。将肝微粒体和重组酶在37℃下在含和不含NADPH生成体系(由1mM NADP+、10mM葡萄糖-6-磷酸和1单位葡萄糖-6-磷酸脱氢酶组成)的pH 7.4的50mM磷酸钾缓冲液中培养。同样在37℃下,将原发肝细胞在Williams E培养基中悬浮培养。在0-4h的培养时间后,用乙腈(最终浓度约30%)终止培养混合物,并将蛋白质在约15000×g下离心出。将如此终止的样品直接进行分析或储存在-20℃下直至分析。
通过带有紫外和质谱检测的高效液相色谱(HPLC-UV-MS/MS)进行分析。为此,将培养样品的上清液用合适的C18反相柱和乙腈与10mM的甲酸铵水溶液或0.05%甲酸的可变流动相混合物进行层析。将UV色谱图数据结合质谱数据用于代谢物的鉴定、结构解析和定量估计,以及用于本发明化合物在培养混合物中的定量代谢减少。
B-8.Caco-2渗透性试验
借助Caco-2细胞系——已在体外建立用于胃肠屏障渗透性预测的模型(Artursson,P.和Karlsson,J.(1991).Correlation between oral drug absorption inhumans and apparent drug permeability coefficients in human intestinalepithelial(Caco-2)cells.Biochem.Biophys.175(3),880-885)——确定试验物质的渗透性。将Caco-2细胞(ACC No.169,DSMZ,Deutsche Sammlung von Mikroorganismen undZellkulturen,Braunschweig,Germany)种在具有插管的24孔板中并培养14至16天。为进行渗透性研究,将试验物质溶解在DMSO中并用转移缓冲液(Hanks缓冲盐溶液,Gibco/Invitrogen,含19.9mM葡萄糖和9.8mM HEPES)稀释至最终试验浓度。为了测定试验物质从顶端到基底外侧的渗透性(PappA-B),将包含试验物质的溶液施加到Caco-2细胞单层的顶面上,并将转移缓冲液施加到基底外侧面上。为了测定试验物质从基底外侧到顶端的渗透性(PappB-A),将包含试验物质的溶液施加到Caco-2细胞单层的基底外侧面上,并将转移缓冲液施加到顶面上。在实验开始时,从各自的供体室(donor compartment)中取样以确保质量平衡。在37℃下培养两个小时后,从两个室中取样。通过LC-MS/MS分析样品并计算表观渗透系数(Papp)。对于各细胞单层,测定荧光黄的渗透性以确保细胞层完整性。在运行的各试验中,还确定了阿替洛尔(低渗透性的标记物)和柳氮磺胺吡啶(主动排泄的标记物)的渗透性作为质量控制。
B-9.hERG钾电流试验
hERG(人ether-a-go-go相关基因)钾电流对人心肌细胞动作电位的复极化有显著贡献(Scheel等人,2011)。通过药物抑制这种电流在极少数情况下可引起潜在致命的心脏心律失常,并因此在药物开发过程的早期进行研究。
本文所使用的功能性hERG试验基于稳定表达KCNH2(HERG)基因的重组HEK293细胞系(Zhou等人,1998)。这些细胞在自动化系统(PatchlinerTM;Nanion,Munich,Germany)中通过“全细胞电压钳”技术(Hamill等人,1981)进行研究,所述自动化系统控制膜电压并在室温下测量hERG钾电流。PatchControlHTTM软件(Nanion)控制Patchliner系统、数据采集和数据分析。电压由2个受PatchMasterProTM软件控制的EPC-10quadro放大器(两者:HEKAElektronik,Lambrecht,Germany)控制。具有中等电阻的NPC-16芯片(~2MΩ;Nanion)充当平面基底以用于电压钳实验。
将NPC-16芯片用细胞内和细胞外溶液(参见Himmel,2007)以及细胞悬浮液填充。在形成千兆欧姆密封和建立全细胞模式(包括几个自动质量控制步骤)后,将细胞膜在-80mV的保持电位下钳住。随后的电压钳方案将指令电压变至+20mV(持续1000ms)、-120mV(持续500ms)并变回到-80mV的保持电位;每12s重复一次这种过程。在最初的稳定阶段(约5-6分钟)后,将试验物质溶液通过吸移管以增加的浓度(例如0.1、1和10μmol/l)(每一浓度暴露约5-6分钟)引入,接着进行几个洗涤步骤。
由电位从+20mV变化到-120mV所产生的向内的“尾”电流的幅值用于将hERG钾电流定量并被描述为时间的函数(IgorProTM软件)。在各时段(例如试验物质前的稳定阶段、试验物质的第一/第二/第三浓度)结束时的电流幅值用于建立浓度/效应曲线,由其计算试验物质的半最大抑制浓度IC50。
Hamill OP,Marty A,Neher E,Sakmann B,Sigworth FJ.Improved patch-clamptechniques for high-resolution current recording from cells and cell-freemembrane patches.Pfluegers Arch 1981;391:85-100。
Himmel HM.Suitability of commonly used excipients forelectrophysiological in-vitro safety pharmacology assessment of effects onhERG potassium current and on rabbit Purkinje fiber action potential.JPharmacol Toxicol Methods 2007;56:145-158。
Scheel O,Himmel H,Rascher-Eggstein G,Knott T.Introduction of amodular automated voltage-clamp platform and its correlation with manualhuman ether-a-go-go related gene voltage-clamp data.Assay Drug Dev Technol2011;9:600-607。
Zhou ZF,Gong Q,Ye B,Fan Z,Makielski JC,Robertson GA,JanuaryCT.Properties of hERG channels stably expressed in HEK293cells studied atphysiological temperature.Biophys J 1998;74:230-241。
C.药物组合物的工作实施例
本发明的化合物可被转化成如下的药物制剂:
片剂:
组成:
100mg本发明的化合物、50mg乳糖(一水合物)、50mg玉米淀粉(天然的)、10mg聚乙烯吡咯烷酮(PVP 25)(BASF,Ludwigshafen,Germany)和2mg硬脂酸镁。
片剂重量212mg。直径8mm,曲率半径12mm。
制备:
将本发明的化合物、乳糖和淀粉的混合物用5%PVP于水中的溶液(w/w)造粒。将颗粒干燥,然后与硬脂酸镁混合5分钟。将该混合物用常规压片机压片(片剂规格见上)。用于压片的指导值为15kN的压力。
用于口服给药的悬浮剂:
组成:
1000mg本发明的化合物、1000mg乙醇(96%)、400mg(购自FMC,Pennsylvania,USA的黄原胶)和99g水。
10ml口服悬浮剂相当于单一剂量的100mg本发明的化合物。
制备:
将Rhodigel悬浮于乙醇中;将本发明的化合物加入到悬浮液中。边搅拌边加入水。将混合物搅拌约6h,直到Rhodigel完全溶胀。
用于口服给药的溶液剂:
组成:
500mg本发明的化合物、2.5g聚山梨醇酯和97g聚乙二醇400。20g口服溶液剂相当于单一剂量的100mg本发明的化合物。
制备:
将本发明的化合物在搅拌下悬浮于聚乙二醇和聚山梨醇酯的混合物中。持续搅拌操作直到本发明的化合物完全溶解。
静脉内(i.v.)溶液剂:
将本发明的化合物以低于饱和溶解度的浓度溶于生理上可接受的溶剂(例如等渗盐溶液、葡萄糖溶液5%和/或PEG 400溶液30%)中。将所得溶液进行无菌过滤并分配于无菌和无热原的注射容器中。
Claims (16)
1.具有系统名称为ent-N-(2-氨基-3-氟-2-甲基丙基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
2.具有系统名称为ent-N-(2-氨基-5,5,5-三氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
3.具有系统名称为ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
4.具有系统名称为ent-N-(2-氨基-5-氟-2-甲基戊基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
5.具有系统名称为ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
6.具有系统名称为ent-N-(2-氨基-4,4-二氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
7.具有系统名称为rac-N-(2-氨基-4-氟-2-甲基丁基)-6氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(外消旋体)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
8.具有系统名称为ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体A)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
9.具有系统名称为ent-N-(2-氨基-4-氟-2-甲基丁基)-6-氯-8-[(2,6-二氟苄基)氧基]-2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺(对映异构体B)和以下结构式的化合物
及其N-氧化物、盐、溶剂合物、所述N-氧化物的盐以及所述N-氧化物和盐的溶剂合物。
10.制备本发明的化合物的方法,其特征在于
[A]在惰性溶剂中,在合适的碱或酸的存在下,使式(I)的化合物反应
其中
T1代表(C1-C4)-烷基或苄基,
得到式(II)的羧酸
随后在惰性溶剂中,在酰胺偶联条件下,使其与选自以下的胺反应,
任选地在催化剂的存在下,将任选存在的保护基团氢解除去,
并且将所得到的化合物任选地用合适的(i)溶剂和/或(ii)酸或碱转化成它们的溶剂合物、盐和/或所述盐的溶剂合物。
11.如权利要求1至9中任一项所定义的化合物,其用于治疗和/或预防疾病。
12.如权利要求1至9中任一项所定义的化合物用于制备用于治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症和动脉硬化的药物的用途。
13.药物,其包含与惰性的、无毒的、药学上合适的赋形剂结合的如权利要求1至9中任一项所定义的化合物。
14.药物,其包含如权利要求1至9中任一项所定义的化合物,所述化合物与选自以下的其他活性化合物结合:有机硝酸盐、NO供体、cGMP-PDE抑制剂、抗血栓形成剂、降血压剂和脂类代谢调节剂。
15.根据权利要求13或14所述的药物,其用于治疗和/或预防心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾衰竭、血栓栓塞病症和动脉硬化。
16.使用有效量的至少一种如权利要求1至9中任一项所定义的化合物或如权利要求13至15中任一项所定义的药物来治疗和/或预防人和动物的心力衰竭、心绞痛、高血压、肺高血压、局部缺血、血管病症、肾功能不全、血栓栓塞病症和动脉硬化的方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14166911.9 | 2014-05-02 | ||
EP14166911 | 2014-05-02 | ||
PCT/EP2015/059350 WO2015165970A1 (de) | 2014-05-02 | 2015-04-29 | 6-chlor-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106507673A true CN106507673A (zh) | 2017-03-15 |
Family
ID=50693467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580034595.5A Pending CN106507673A (zh) | 2014-05-02 | 2015-04-29 | 6‑氯取代的咪唑并[1,2‑a]吡啶甲酰胺及其作为可溶性鸟苷酸环化酶刺激剂的用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170101407A1 (zh) |
EP (1) | EP3137465A1 (zh) |
JP (1) | JP2017514901A (zh) |
CN (1) | CN106507673A (zh) |
CA (1) | CA2947372A1 (zh) |
WO (1) | WO2015165970A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108358797A (zh) * | 2018-04-20 | 2018-08-03 | 南京农业大学 | 一种烷基甘氨酸的合成方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106470995A (zh) * | 2014-05-02 | 2017-03-01 | 拜耳医药股份有限公司 | 用于治疗心血管疾病的作为可溶性鸟苷酸环化酶刺激物的咪唑并[1,2‑a]吡啶类 |
WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
WO2024102699A1 (en) * | 2022-11-07 | 2024-05-16 | ELANCO US, Inc. | Guanylate cyclase (gc) stimulator formulations and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0266890A1 (en) * | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
WO1989003833A1 (en) * | 1987-10-30 | 1989-05-05 | Aktiebolaget Hässle | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS |
CN103608347A (zh) * | 2011-05-30 | 2014-02-26 | 安斯泰来制药株式会社 | 咪唑并吡啶化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624214B2 (en) * | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US9126998B2 (en) * | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
-
2015
- 2015-04-29 EP EP15721635.9A patent/EP3137465A1/de not_active Withdrawn
- 2015-04-29 CA CA2947372A patent/CA2947372A1/en not_active Abandoned
- 2015-04-29 JP JP2017508756A patent/JP2017514901A/ja active Pending
- 2015-04-29 CN CN201580034595.5A patent/CN106507673A/zh active Pending
- 2015-04-29 WO PCT/EP2015/059350 patent/WO2015165970A1/de active Application Filing
- 2015-04-29 US US15/308,200 patent/US20170101407A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0266890A1 (en) * | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
WO1989003833A1 (en) * | 1987-10-30 | 1989-05-05 | Aktiebolaget Hässle | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS |
CN103608347A (zh) * | 2011-05-30 | 2014-02-26 | 安斯泰来制药株式会社 | 咪唑并吡啶化合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108358797A (zh) * | 2018-04-20 | 2018-08-03 | 南京农业大学 | 一种烷基甘氨酸的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2017514901A (ja) | 2017-06-08 |
CA2947372A1 (en) | 2015-11-05 |
EP3137465A1 (de) | 2017-03-08 |
WO2015165970A1 (de) | 2015-11-05 |
US20170101407A1 (en) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10662185B2 (en) | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | |
CN104955823B (zh) | 羧基取代的咪唑并[1,2‑a]吡啶甲酰胺及其作为可溶性鸟苷酸环化酶的刺激物的用途 | |
US9126998B2 (en) | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
CN103842363B (zh) | 取代的咪唑并哒嗪类化合物及其用途 | |
TW201605850A (zh) | 經取代吡唑并[1,5-a]吡啶-3-羧醯胺類及其用途 | |
US20140128424A1 (en) | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | |
CN106103438A (zh) | 取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途 | |
CN106414440A (zh) | 芳基和杂芳基取代的咪唑并[1,2-a]吡啶-3-羧酰胺及其用途 | |
US20170217954A1 (en) | Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
CN106459047A (zh) | 咪唑并[1,2‑a]吡啶作为可溶性鸟苷酸环化酶的刺激物用于治疗心血管疾病 | |
JP2016527295A (ja) | 置換イミダゾ[1,2−a]ピラジンカルボキサミドおよびその使用 | |
CN106507673A (zh) | 6‑氯取代的咪唑并[1,2‑a]吡啶甲酰胺及其作为可溶性鸟苷酸环化酶刺激剂的用途 | |
CN107257796A (zh) | 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途 | |
CN106470995A (zh) | 用于治疗心血管疾病的作为可溶性鸟苷酸环化酶刺激物的咪唑并[1,2‑a]吡啶类 | |
CN106459037A (zh) | 用于治疗心血管疾病的N‑(2‑氨基‑5‑氟‑2‑甲基戊基)‑8‑[(2,6‑二氟苄基)氧基]‑2‑甲基咪唑并[1,2‑a]吡啶‑3‑甲酰胺的对映异构体及其二‑和三氟衍生物的对映异构体 | |
CN107074772A (zh) | 取代的喹啉‑4‑甲酰胺及其用途 | |
CN107001361A (zh) | 杂芳基取代的咪唑并[1,2‑a]吡啶及其用途 | |
CN107108658A (zh) | 取代的环状嘧啶及其用途 | |
CN107567451A (zh) | 作为用于治疗心血管疾病的可溶性鸟苷酸环化酶(sgc)刺激物的n‑取代的8‑[(2,6‑二氟苄基)氧基]‑2,6‑二甲基咪唑并[1,2‑a]吡嗪‑3‑甲酰胺衍生物 | |
CN107567446A (zh) | 取代的吡唑并[1,5‑a]吡啶‑3‑甲酰胺及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1231058 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170315 |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1231058 Country of ref document: HK |